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ABSTRACT 
Respiratory syncytial virus (RSV) and influenza A (IAV) and B (IBV) viruses 
infect humans throughout their life with exceptionally high rates of re-infection. 
Serological assays are commonly used to diagnose and characterize host immune 
responses against microbial pathogens acquired by natural infection or vaccination. 
The current methods are mostly based on enzyme immunoassay (EIA) or other 
conventional methods in a single analyte format. Presently, there is a need to shift 
from single analytical methods to microarray format which enables the detection of 
antibodies against multiple targets in a rapid and cost-effective manner. 
In this study, a highly sensitive single analyte EIA method was used for 
serological analyses in children’s sera. In addition, multiplex microarray 
immunoassay (MAIA) methods were developed for rapid and simultaneous 
detection of IgG antibodies against seven viral antigens (H1N1pdm09 vaccine ag, 
IAV H1N1, IAV H3N2, IBV Victoria, IBV Yamagata, RSV and adenovirus hexon 
protein). We found out that MAIA is well suitable for large-scale serosurveillance 
and vaccine immunity studies. We followed-up virus-specific immunity by MAIA 
in response to natural infection and vaccination in a large cohort of 0-2 year old 
children. Our serological findings showed a high rate of respiratory virus infections 
and reinfections in young children. 
The applicability of MAIA in vaccine immunity studies was also analysed. We 
developed a specific, sensitive, sample and antigen saving assay for simultaneous 
detection of IgM and IgG antibodies against H1N1pdm09 vaccine ag and IBV 
Yamagata. MAIA showed excellent correlation with EIA and a good correlation 
with hemagglutination inhibition assay in measurement of vaccine-induced 
antibodies in sera of Pandemrix-vaccinated adults.  
KEYWORDS: multiplexing, microarray, immunoassay, serology, RSV, influenza, 
pandemic, vaccine, antibodies, epidemiology 
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TIIVISTELMÄ 
Respiratory syncytial virus (RSV) ja influenssa A- (IAV) ja B(IBV)-virukset ovat 
merkittäviä ylähengitystieinfektioiden aiheuttajia koko ihmisen elinkaaren ajan. 
RSV:n ja influenssan aiheuttamat infektiot voivat joskus olla vakavia tai jopa 
henkeä uhkaavia erityisesti pienillä lapsilla ja ikäihmisillä. Nykyiset 
serodiagnostiset menetelmät perustuvat entsyymi-immunologisiin (EIA) ja muihin 
määritysmenetelmiin, joissa immuunivastetta voidaan tutkia kerrallaan vain yhtä 
taudinaiheuttajaa kohtaa. Tällä hetkellä on seerumin vasta-ainetutkimusten osalta 
suuri tarve siirtyä monianalyyttisiin menetelmiin, jotka olisivat nopeampia ja 
kustannustehokkaampia kuin nykyiset tutkimusmenetelmät. 
Tässä tutkimuksessa on käytetty herkkiä EIA-menetelmiä pienten lasten ja 
influenssarokotettujen henkilöiden seerumien virusspesifisen immuunivasteen 
tutkimiseen. Työssä on myös kehitetty monianalyyttinen mikrosiruperusteinen 
immunomääritysmenetelmä (MAIA) samanaikaiseen seerumin IgG-luokan vasta-
aineiden mittaamiseen eri influenssavirusantigeeneja, RSV:tä ja adenoviruksen 
heksoniproteiinia kohtaan. Tutkimuksemme osoittivat, että hengitysteiden virus-
infektiot ja yllämainittujen virusten aiheuttamat uusintainfektiot ovat erittäin 
tavallisia pienillä lapsilla. MAIA-menetelmää sovellettiin myös aikuisten 
influenssarokotevasteiden analyysiin. Menetelmää kehitettiin edelleen siten, että 
näytteestä voitiin samalla kertaa mitata seerumin IgG- ja IgM-luokan vasta-aineita 
eri IAV- ja IBV-virusantigeeneja kohtaan. Menetelmä osoittautui erittäin spesifi-
seksi, herkäksi ja näytettä ja antigeeneja säästäväksi ja tulokset olivat hyvin 
yhtenevät muiden perinteisten vasta-ainetutkimusmenetelmien kanssa. Kehittä-
mämme MAIA-menetelmä toimi erittäin hyvin ja sen voitiin osoittaa sopivan 
erinomaisesti laajojen väestön seerumiaineistojen ja virusrokotevasteiden 
analyysiin. 
HAKUSANAT: monianalytiikka, mikrosiru, immunomääritysmenetelmät, serologia, 
RSV, influenssa, pandemia, virusrokotteet, vasta-aineet, epidemiologia 
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Ab  antibody 
Ag antigen 
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 Introduction 
Large-scale screening and estimation of immunity and exposure to viral pathogens 
are essential for understanding the risk factors of infection and population‐scale 
patterns of transmission (Arnold et al., 2018). Additionally, the impact of prior 
immunity in a population is important for estimation of the need for subsequent 
vaccinations. Improved evaluation of vaccines has impact on public health.  The 
determination of antibody concentration in sera is considered the gold standard 
method to estimate humoral immunity to natural infection or vaccination (Plotkin, 
2010). Enzyme immunoassays (EIA) are broadly used to measure antibody 
responses against different viruses. Nowadays, in most clinical laboratories, 
multiple single analyte EIAs are needed to determine antibody responses to 
different viruses.  
Influenza A viruses are highly variable and virus mutations pose a risk to 
overcome species barriers causing human infections with animal influenza 
(Cauldwell et al., 2014). Such infections with antigenically novel viruses have led 
to worldwide pandemics. It is very difficult to predict the time of future pandemics. 
The ongoing influenza epidemics highlight the need for constant monitoring of 
circulating virus strains and virus-host interactions. Two of the most common 
methods for measuring serum antibody to influenza and evaluation the effects of 
influenza vaccines are the hemagglutination inhibition (HI) and virus neutralization 
(VN) assays (Truelove et al., 2016). With these methods large-scale 
serosurveillance or vaccine studies for influenza immunity are very laborious and 
time consuming. In order to facilitate the analysis of population immunity and the 
rapid assessment and comparison of vaccination efficacy, new multiplex high-
throughput assays are highly desirable to supplement standard methods. New 
diagnostic and analytical methods will improve infectious disease surveillance and 
lead to a better understanding of vaccine and natural infection induced immunity. 
In the last decade, various microarray assays for infectious disease research have 
been developed and they show great potential to achieve these goals (Yuk et al., 
2004; Tang et al., 2005; Negm et al., 2015; Schepp et al., 2019).  
Multiplexing technology emerged about 20 years ago and has developed 
extensively since then. Currently, multiplex assays are widely used in clinical 
Anna Kazakova 
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diagnostics (Navidad et al., 2013; Hanson and Couturier, 2016; Kim et al., 2016), 
biomedicine research (Schaffer et al., 2015), food safety assessment (Yoon and 
Kim, 2012), and environmental monitoring (Yu et al., 2011; Hanson and Couturier, 
2016). Multiplex assays have been actively developed also for applications in the 
fields of immunology, microbiology, and virology (Cannon et al., 2010; Zhang et 
al., 2013; Villar-Vázquez et al., 2016). Multiplex protein-based immunoassays are 
used to analyse antibody responses to infectious diseases (Talha et al., 2016) and 
nucleic acid-based multiplex assays are used for virus detection and genotyping 
(Martínez et al., 2015; Quiñones et al., 2017). Multiplex assays substantially 
improve the detection and control of viral respiratory and other types of infections 
and also facilitate the rapid characterization of new viruses. 
In contrast to EIAs, a considerable amount of information can be generated 
from a single sample aliquot in a single analysis by multiplex immunoassay. 
Multiplex immunoassays can simultaneously detect different antibody types 
against multiple analytes in a single sample (Gomez et al., 2010; Liu et al., 2013). 
They facilitate high sample throughput, reduce labour and require small sample 
volumes and antigen amounts. Rapid and reliable screening of a large panel of 
respiratory viruses is of great importance for monitoring epidemic waves and the 
immune status in the population. Simultaneous detection of several different virus-
specific antibodies on one platform should result in faster data accumulation. The 
method has important application in vaccine efficacy studies and studies of 
infectious diseases in young children. Efficient large-scale screening of respiratory 
virus antibodies in young children is important for estimating the need for 
vaccination and the potential use of antiviral drugs. In vaccine development, 
serological surveys facilitate adequate decisions on immunization schedules and 
targeted age groups.  
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 Review of the literature 
2.1 Traditional serodiagnostic methods 
Serology enables the assessment of immunological status by measuring antibody 
levels against microbial pathogens in serum samples. Serological assays are 
essential for vaccine evaluation and the diagnosis of an infection. Serological 
surveys are also frequently used to determine the incidence or prevalence of an 
infectious disease in a human population or in animals. Such epidemiological 
data indicates the susceptibility and immunity level in the target population. The 
presence of antibodies in a serum sample can indicate past exposure to a virus or 
vaccination as well as cross-reaction to related viruses. The measurement of 
antigen-specific antibodies is the most widely used parameter to evaluate the 
immunogenicity of vaccines. Antibodies play an essential role in the protection 
of a host from infectious diseases. Neutralizing antibodies block the infection and 
they thus correlate with protection. For most vaccines induction of vaccine 
antigen-specific antibodies is commonly considered as a good parameter 
correlating with host protection and vaccine efficacy (Plotkin, 2010). The 
determination of antibody isotype allows distinguishing recent exposure to the 
pathogen from past immunity. IgG isotype antibodies correlate with 
immunological memory and they are the most commonly examined immune 
markers in vaccine research. IgA and IgM isotypes, however, also play an 
important role in immunity induced by vaccines. The presence of antivirus IgM 
antibodies indicates current or recent infection as they are produced early after 
infection or vaccination (James, 1990). 
Serological methods are based on the analysis of a specific interaction between 
antigen and antibody. There is a wide range of serological techniques used in the 
diagnostics of infectious diseases: enzyme-linked immunosorbent assay (ELISA), 
haemagglutination inhibition (HI) test, single radial haemolysis (SRH) assay, 
immunofluorescence assay (IFA), multiplex immunoassays, complement fixation 
(CF) test, immunoblotting, virus neutralization (VN) assay, radioimmunoassays 
and latex agglutination.  
Immunostaining is one of the techniques where enzyme-antibody conjugates 
are used to stain specific molecules on cells to visualise them in a tissue or in cells 
Anna Kazakova 
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to examine intracellular structures (Maity, Sheff and Fisher, 2013). In 
immunoblotting or immunoblot assays, enzyme-antibody conjugates are used to 
identify specific antigens, e.g. viral proteins that have been transferred to an 
absorbent membrane or to detect antibodies from patient samples specific to the 
immobilised antigens on the membrane (Mahmood and Yang, 2012). A patient 
serum sample is incubated with the membrane, followed by incubation with anti-
human antibody conjugated with an enzyme. Antibody-antigen binding is 
visualized by the addition of a substrate and a colour reaction. The assay is 
commonly used as a confirmatory assay, especially for diagnosing HIV infection 
(Wald and Ashley‐Morrow, 2002). Immunofluorescence assay (IFA) is used for the 
detection of IgM and IgG antibodies against virus-infected cells on glass 
microscope slides. Bound antibodies from patient samples are detected by 
fluorescein-conjugated anti-human antibodies using a fluorescence microscope 
(Malan et al., 2003). 
The complement fixation test (CF) is applicable to a large number of viral 
infections (Rice, 1961; Swack, Gahan and Hausler, 1992). In the CF test, virus 
antigen, sheep red blood cells, anti-sheep red blood cells antibodies and fixed 
amount of complement are added to a diluted serum sample. If patient does not 
have antibodies against antigen of interest, the complement will cause haemolysis 
of sheep red blood cells and the solution turns pink colour. However, the CF test is 
time consuming, labour intensive and not sensitive (Bannai et al., 2013; Shibata et 
al., 2013). Comparison of CF test and hemagglutination inhibition assay showed 
that the test lack strain specificity for influenza antibody responses and is not 
sensitive enough to assess the antibody responses to influenza vaccination (Prince 
and Leber, 2003). Nowadays, the method is not very commonly used in clinical 
diagnostics due to its complexity compare to other serological methods and has 
been replaced by newer and more sensitive techniques. Serological methods 
frequently used in research to determine the immunological response to influenza 
vaccine and/or natural infection include haemagglutination inhibition (HI) test, 
virus neutralization (VN) assay, single radial haemolysis (SRH) assays and enzyme 
immunoassay-based testing (Landolt, Townsend and Lunn, 2014; Medicines 
Agency, 2016; Trombetta et al., 2018). 
2.1.1 Hemagglutination inhibition assay 
Humoral immune responses to influenza vaccination are primarily analysed by the 
hemagglutination inhibition (HI) assay (Trombetta, Perini, Mather, Temperton, 
Montomoli, et al., 2014). HI test is frequently used in diagnostic laboratories and 
essentially performed according to a WHO standard protocol (Hirst, 1942; World 
Health Organization. and WHO Global Influenza Surveillance Network., 2011). HI 
Review of the literature 
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assay is primarily used for influenza viruses but also the assay is an important tool 
to study other groups of viruses  ̶ for example, paramyxoviruses, togaviruses, 
flaviviruses, and bunyaviruses (L’vov et al., no date; Rösler et al., 2013). The 
principle of the hemagglutionation inhibition assay is shown in Figure 1. Virus 
surface proteins (e.g. hemagglutinin on the surface of influenza virus) have the 
ability to bind to sialic acid-containing molecules (receptors) on the surface of red 
blood cells (RBCs). Haemagglutination is a process known as a formation of 
lattice-like structure in a suspension in the presence of virus that can agglutinate 
RBCs (Pedersen, 2014). Antibodies specific to the virus surface proteins are able to 
inhibit the hemagglutination process. Following influenza vaccination, antibodies 
specific to hemagglutinin are produced. Haemagglutinin specific antibodies bind to 
the influenza virus and prevent the attachment of the virus to the RBCs. The 
process is called hemagglutination inhibition. Haemagglutination will not be 
observed if antibodies to the virus are present until the antibodies are fully diluted. 
The main benefit of the assay is its relative simplicity and low cost. The assay does 
not require special equipment as the results are visually read. Hemagglutionation 
inhibition is observed when RBCs sediment to the bottom of the well and form a 
small pellet. A fixed amount of influenza virus is added to the wells, usually 4 
hemagglutinin (HA) units/25 µL or 8 HA units/50 µL. Serum samples are prepared 
in two-fold serial dilutions and added along a row of wells. The highest antibody 
dilution which is able to clearly inhibit hemagglutionation is considered as the HI 
antibody endpoint titre.  
Anna Kazakova 
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Figure 1.  Schematic principle of a hemagglutionation inhibition assay. Serial dilutions of serum 
samples are added into wells in a 96-well plate. Anti-influenza antibodies present in 
serum samples prevent virus binding to RBCs causing haemagglutination inhibition. 
The result is read visually by eye observing a small pellet of sedimenting RBCs at the 
bottom of the well. 
Despite its wide use and benefits, the HI test has many limitations. First of all the 
interpretation of the HI test can be quite subjective and there is significant variation 
from one laboratory to another (Wagner et al., 2012; Wood et al., 2012). 
Researchers assess the outcome of the test visually and it is sometimes hard to 
accurately determine the final antibody dilution that inhibits hemagglutionation as 
the results may be unclear due to partial inhibition of hemagglutination. Species 
selection and freshness of RBCs is critical for reliable results (Wibawa et al., 2012; 
Ovsyannikova et al., 2014). Since samples can only be tested in serial dilutions, a 
high degree of specificity cannot be achieved for the determination of antibody 
concentrations. Multiple replicates are needed to improve the accuracy of the 
results, which makes the assay quite labour intensive. The assay is not very suitable 
for large-scale studies as serial dilutions of only 7 serum samples can be tested in 
one 96-well microtiter plate. The failure of the assay to differentiate between 
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immunoglobulin isotypes is an additional disadvantage. Poor hemagglutination of 
recent and contemporary avian influenza viruses and low sensitivity for influenza 
B viruses are further limitations of the HI assay (Rowe et al., 1999; de Jong et al., 
2003; Stephenson et al., 2009; Trombetta et al., 2018).  
Antibody endpoint titers determined by the HI test are known to correlate 
well with protective immunity and allow the estimation of a risk for influenza 
infection and thus the efficacy of the vaccine (Noah et al., 2009). An HI titre of 
1:40 or higher is generally accepted as a protective level and it corresponds to a 
50% reduction in the risk of contracting influenza infection in a susceptible 
population (FOX et al., 1982; Ng et al., 2013).  High HI antibody titres are 
strongly associated with the protection against clinical influenza infection 
(Hobson et al., 1972; Plotkin, 2001; de Jong et al., 2003). Coudeville et al., 2010 
have revealed a significant and positive relationship between HI titre and clinical 
protection against influenza using a meta-analytical approach where HI data from 
multiple studies were analysed (Coudeville et al., 2010). The results indicate that 
the immunogenicity data allows the prediction of the efficacy of inactivated 
influenza vaccines. However, HI antibody titre of 1:40 remains a theoretical 
immunological correlate of protection. It is well known that, influenza infection 
can sometimes be acquired even by a vaccinated individual with a theoretically 
protective antibody level (Plotkin, 2008). Nevertheless, according to the 
guidelines for pandemic influenza vaccines, HI titre of 1:40 or higher is currently 
the best available parameter to estimate vaccine induced protective immunity 
(Noah et al., 2009).  
2.1.2 Virus neutralization (VN) 
Virus neutralization (VN) test is a reliable method to detect antiviral immunity as it 
only detects antibodies that can neutralise the virus and block virus replication 
(Payne, 2017). The method is not used for routine diagnosis but has been applied to 
determine neutralizing serum antibody titers to some viral vaccines e.g. measles 
(Kontio et al., 2016) and poliovirus types 1, 2 and 3 (Resik et al., 2017), to 
quantify serum antibodies to influenza A and B and parainfluenza 1 and 2 viruses 
(Frank et al., 1980), to differentiate among highly related arboviruses (Kuno, 2003) 
and enteroviruses serotyping (Zhu et al., 2018). VN assay is often used for 
measuring anti-influenza antibodies as an alternative method to HI assay (Truelove 
et al., 2016). VN assay is also called a microneutralization assay when performed 
in 96-well microtiter plate (Okuno et al., 1990). VN assay is more resource 
intensive, time consuming and laborious to perform compared to the HI assay. 
While HI assay measures the ability of antibodies to bind to the virus and inhibit 
Anna Kazakova 
 18 
RBCs agglutination, VN assay measures antibodies that can bind to the virus and 
block its ability to infect target cells.  
VN is performed in a similar manner to HI, i.e. incubating serial dilutions of 
serum samples with fixed amount of virus to determine which serum dilution will 
inhibit virus replication. In VN assay a live virus is used and the killing of the cells 
by the virus is determined as a plaque formation. Antibodies that block virus 
infectivity and as a result prevent the killing of the cells, are called neutralizing 
antibodies. Neutralizing antibodies are able to inhibit viral attachment, entry, and 
the release of progeny virions (Trombetta, Perini, Mather, Temperton, Montomoli, 
et al., 2014). VN titre is the highest serum dilution that induces a 50% inhibition of 
virus growth.  
Although the VN assay provides a better correlation to protective immunity, 
the assay is more time‐consuming and expensive and it is considered to be difficult 
to standardize between the laboratories (Stephenson et al., 2009; Wood et al., 
2012). There are many studies comparing the performance of HI and VN methods 
for measuring anti-influenza antibodies. In general, HI and VN assay comparisons 
have shown a good correlation between the two methods especially for seasonal 
influenza A virus antibodies (Truelove et al., 2016; Haveri et al., 2019). However, 
a study on the reproducibility tests for H1N1 pandemic influenza A virus 
antibodies revealed up to 6 or 7-fold inter-laboratory variation in HI and VN test 
results, respectively (Wagner et al., 2012). Poor reproducibility of the VN assay 
and the lack of standardization poses a problem on the reliability of the method for 
the determination of influenza vaccine efficacy (Laurie et al., 2015). The 
investigation of VN assay inter-laboratory variation for detection of anti-influenza 
antibody was performed in 11 laboratories from eight countries (Stephenson et al., 
2007). As there is no established common protocol for VN assays, the laboratories 
used own established in-house protocols. VN assays displayed significant inter-
laboratory variability. The between laboratory geometric coefficients of variation 
were 256 –359 % depending on the virus strain. 
Despite its sensitivity and specificity, the VN assay is unsuitable for large-scale 
studies. The need to handle wild-type virus and cells, poor reproducibility and the 
time required for the assay performance are the main limitations of the assay. 
Presently, VN titre value which correlates with protection is undefined. VN titre 
equal to a HI titre of 1:40 varies between laboratories and cannot be easily 
standardised (Stephenson et al., 2007). VN is also unable to discriminate different 
immunoglobulin classes in antibody responses.  VN is useful in analysing humoral 
immune responses to avian strains of influenza, especially when HI test fails to 
detect antibodies against these viruses (Rowe et al., 1999; Ansaldi et al., 2004). 
However, studies of highly pathogenic avian strains such as H5 and H7, require 
work in biosafety level 3 (BSL-3) laboratory, additional safety precautions and 
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extensive training for laboratory personnel which are associated with high running 
costs.  
2.1.3 Single radial haemolysis assay 
Single radial haemolysis (SRH) was developed in 1975, combining the benefits 
of two different methods. The accuracy of SRH is combined with the sensitivity 
of the HI test (Russell, McCahon and Beare, 1975; Schild, Pereira and 
Chakraverty, 1975). SRH assay was developed for virus infections such as 
rubella, mumps, influenza, adenovirus, dengue and Japanese encephalitis virus 
(Russell et al., 1978; Fulton et al., 1984; Chan et al., 1985; Trombetta et al., 
2015). However, the main use of this technique remains in the screening for 
influenza antibodies (Trombetta, Perini, Mather, Temperton, Montomoli, et al., 
2014). The principle of the SRH assay is shown in Figure 2. The technique relies 
on the passive haemolysis of virus-treated red blood cells by virus-specific 
antibody and complement.  
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Figure 2.  Schematic principle of single radial haemolysis assay. Virus-coated sheep RBCs and 
guinea pig complement are mixed with agar and poured in a plate. A heat-inactivated 
serum sample is added to the well punched in the agarose gel. If there are virus-
specific antibodies in the serum, there will be antigen-antibody complexes following 
complement fixation. Fixed complement causes RBC haemolysis. The result is read 
visually by eye observing a zone of lysis around the well. Virus-specific antibody 
amount present in the test serum corresponds to the measured zone of lysis (in mm2).  
SRH can be used for the antigenic characterization of influenza viruses as it detects 
strain-specific antihaemagglutinin antibody (Lu et al., 2014). Although the assay is 
more laborious than HI assay, the SRH assay is more reproducible than HI assays 
and more sensitive than CF test (Katz, Hancock and Xu, 2011). The greatest 
advantage of the SRH method is its safety as the assay does not require purified or 
concentrated virus. It is performed with inactivated virus and it can be safely 
conducted under BSL-2 conditions (Wood et al., 2001). The HI test, VN and SRH 
have shown a good agreement with each other for analysing anti-influenza virus 
antibodies (Morley et al., 1995; Trombetta et al., 2018). However, for influenza B 
viruses, the sensitivity of SRH was higher than that of the HI test in detecting 
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antibodies. The great advantage of SRH is its ability to detect antibodies against 
avian influenza viruses in contrast to the HI test. A previous study showed that 
SRH and VN tests provide sensitive determination of vaccine-induced antibodies 
against avian influenza viruses (Stephenson et al., 2003). Meanwhile, the HI test 
was shown to underestimate antibody responses against avian influenza viruses.  
2.1.4 Enzyme immunoassays 
For many virus infections, enzyme immunoassay (EIA) is the most commonly used 
serological assay. EIA enables accurate and sensitive detection of the antigen or 
antibody and it is widely used in clinical laboratories and biomedical research. A 
wide variety of EIA kits for different applications are commercially available. 
There are many different variations of EIAs, but all of them use the enzyme-
conjugated antibody as a detection molecule (John R. Cowther, 2009). The addition 
of a substrate for the enzyme allows visualisation and quantification of the bound 
antibody to the target molecules. The substrate may be either a chromogen, a 
colourless molecule that is converted into a coloured end product or a fluorogen, a 
nonfluorescent molecule that is transformed into a fluorescent form by the enzyme. 
The assay is typically performed on a 96-well plate format and optical density 
values are read by a plate reader. 
The enzyme-linked immunosorbent assays (ELISAs) are the most widely used 
EIAs. ELISAs were first introduced in the 1971 by Engvall and Perlmann (Engvall 
and Perlmann, 1971) and Van Weemen and Schuurs (Van Weemen and Schuurs, 
1971). ELISA can be performed to evaluate the presence of and quantify specific 
analytes (e.g. antigens, antibodies, proteins, hormones, peptides, etc.) in biological 
samples such as serum, plasma, urea, stool and cell culture supernatants 
(Demerdash et al., 2011; Song et al., 2016; Tsai et al., 2018). Currently, direct, 
indirect, sandwich and competition variations of ELISA exist (John R. Cowther, 
2009). The principles of the ELISA systems are illustrated in Figure 3.  
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Figure 3.  Schematic overview of ELISA techniques. (A) Direct ELISA; (B) Indirect ELISA; (C) 
direct sandwich ELISA; (D) indirect sandwich ELISA.  
Direct ELISA (A) is the simplest form and the base style for other types of ELISA. 
Antigens from the patient sample are attached to a surface of a microtiter plate by 
passive adsorption. After the antigen is immobilised, the plate is washed and the 
surface is blocked with blocking buffer containing detergents and other proteins 
(e.g., albumin, gelatine, casein, and skimmed-milk). The specific to that particular 
antigen enzyme-conjugated antibody will bind followed by colour development 
with addition of appropriate substrate. Alternatively, an antibody from a sample 
immobilized on the surface of microtiter plate can be detected with corresponding 
enzyme-conjugated antigen. Direct ELISA is suitable only for the qualitative 
analysis since the method of antigen or antibody immobilization is not specific 
(Sakamoto et al., 2018). A major disadvantage of the direct ELISA is in 
immobilisation of all proteins from a patient sample, not only analyte of interest. 
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Thus, small concentrations of target antigen or antibody in the sample must 
compete with other proteins when binding to the well surface. An indirect and 
sandwich ELISA systems solve this problem by using capture antigen or antibody 
specific for the target analyte in patient sample.  
In an indirect ELISA (B), serum antibodies from a patient sample against an 
antigen are measured. Fixed amount of the antigen is immobilized in the well of a 
96-well microtiter plate. Antibodies specific to the antigen are bound from the 
serum sample. Secondary enzyme-conjugated antibodies are added to detect bound 
antibodies. The colour end product is produced after incubation with the substrate. 
Produced colour intensity is proportional to the quantity of antigen-specific 
antibodies present in serum sample of a patient.  
Sandwich ELISA systems are used to detect sample antigen and can be divided 
into a direct sandwich ELISA and an indirect sandwich ELISA. In the direct 
sandwich ELISA (C), an antigen from a patient sample binds to immobilised 
capture antibodies specific for the test antigen. The antigen is then detected using 
enzyme-labelled antibodies specific to the antigen. In the indirect sandwich ELISA 
(D), an antigen from a sample is also captured by immobilized antibodies but the 
detection is different. Second antibody from a different species to solid phase 
antibody but specific for the antigen is added and form "antibody-antigen-antibody 
sandwich". Detection is performed by applying enzyme-conjugated antibodies 
specific for species from which the second antibody was prepared. The direct 
sandwich ELISA is technically simpler than indirect method, but the last has 
certain advantages. Production of enzyme-conjugated antibodies against every 
antigen of interest is expensive process. It is avoided in indirect sandwich ELISA 
by using the same enzyme-conjugated anti-species antibodies in a variety of 
antigen detection tests.  
The indirect ELISA is the most commonly used method to detect antigen-
specific antibodies to assess responses to an infection or vaccination. A wide range 
of ELISAs have been developed and they are commercially available for 
measuring antibodies against different viruses. ELISA methods are versatile, 
simple to perform, sensitive and quantifiable. The assay can be performed in many 
laboratories as it requires only equipment with optical scanner to read the results. It 
is possible to measure any antibody isotype (e.g. IgG, IgM, IgA) by ELISA. As 
serum titration is not performed, the quantity of antibodies in a sample can be 
measured more precisely than e.g. in the HI test. High assay reproducibility is an 
additional advantage of the ELISA assays. However, there are certain limitations of 
the assay. Serum samples are required to be properly diluted in order to fall within 
a relatively small dynamic range of the absorbance and antibody quantity (S. X. 
Leng et al., 2008). The major weakness of this method is that only one antibody 
type and antibodies against only one antigen can be measured at the same time, 
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which makes the assay relatively labour-intensive. To facilitate screening of a large 
number of samples, multiplex immunoassays have been actively developed during 
the last decade.  
2.1.5 Serology and influenza vaccines 
In the Unites States, vaccines licensure involves approval from the Food and Drug 
Administration (FDA). After the FDA approves the vaccine, the Advisory 
Committee on Immunization Practices (ACIP) within the Centres for Disease 
Control and Prevention (CDC) considers the risks and benefits of the vaccine and 
develop official federal guidelines for the use of vaccines in the Unites States 
(Grohskopf et al., 2019). In European Union, vaccines are monitored by the 
Committee for Proprietary Medicinal Products (CPMP) under the European 
Medicines Agency (EMA) (Medicines Agency, 2012). In addition to national 
surveillance organizations, international vaccines monitoring is established by the 
World Health Organization (Trombetta, Gianchecchi and Montomoli, 2018).  
Influenza vaccines are needed to fulfil the criteria of immunogenicity based on 
the HI and SRH assays according to the international licensing criteria of the EMA 
and FDA (Trombetta, Perini, Mather, Temperton and Montomoli, 2014). 
Specifically, the vaccines have to clearly increase the geometric mean antibody 
titers and induce seroconversion and establish antibody titers to levels that correlate 
with seroprotection. According to the international licensing criteria of EMA, in 
the age group of 18-60 year-olds a vaccine can be licensed when it induces an 
antibody titre mean fold rise >2.5, a seroconversion rate in ≥40% or seroprotection 
rate in ≥70% of the vaccines (European Committee for Proprietary Medical 
Products, 1997). In adults over 60 years of age, an antibody titre mean fold rise 
>2.0, a seroconversion rate ≥30% and seroprotection rate ≥60% are required. FDA 
established criteria for efficient vaccine-induced responses as a seroconversion rate 
in ≥40% (lower limit of 95% CI) or seroprotection rate in ≥70% (lower limit of 
95% CI) in the vaccinated adults < 65 years of age and in the paediatric population 
(Food and Drug Administration, 2007). For adults ≥ 65 years of age, a 
seroconversion rate in ≥30% (lower limit of 95% CI) or seroprotection rate in 
≥60% (lower limit of 95% CI) are required. If pre-vaccination sample is negative, 
seroconversion means an increase in the HA antibody titers ≥40 in the HI test or 
that the serum haemolysis area is greater than ≥25mm2 in the SRH assay. In case of 
a positive pre-vaccination serum sample, at least a fourfold increase in the HI titre 
or higher than 50% increase in haemolysis area is required. The seroprotection rate 
is counted as a proportion of individuals with HI titre ≥40 or an SRH titre ≥25mm2 
that is considered to correlate with protection.  
Review of the literature 
 25 
The serological criteria described above for the influenza vaccine 
immunogenicity assessment have been the cornerstone for many years (Wijnans 
and Voordouw, 2016). There has been enhanced awareness that it is not the most 
suitable strategy to rely on a single serological cut-off (HI titre ≥40 or an SRH titre 
≥25mm2) for all age groups and different influenza vaccine types (Treanor and 
Wright, 2003; Ohmit et al., 2011; Pfleiderer et al., 2014). This cut-off is well 
defined in healthy adults but not in children. A few studies questioned whether the 
HI assay is the best option to assess the influenza vaccination efficacy in children. 
As young children have little to no previous exposure to influenza vaccination or 
natural influenza infection, higher HI titre levels are required to be set as a 
protective level. Black et al., 2011 showed that HI titre of 1:110 was associated 
with the conventional 50% clinical protection rate against influenza infection in 
children, while the conventional HI titre value of 1:40 was associated with only 
22% protection (Black et al., 2011). In addition, one study in the elderly suggested 
that cell-mediated immunity rather than humoral immunity correlates better with 
the protection against influenza in this age group (McElhaney et al., 2006). 
In 2014, the European Committee for Medicinal Products for Human Use 
(CHMP) incorporated changes to guidelines for the influenza vaccine licensing in 
Europe (Wijnans and Voordouw, 2016). CHMP works under the European 
Medicines Agency (EMA) which is an agency of the European Union. In addition 
to standard HI antibody titre determinations, CHMP requires that neutralizing 
antibodies are quantitated by VN assay and cell-mediated immunity is evaluated in 
a subset of elderly individuals. Moreover, it is required that clinical studies in 
children aged 6–36 months must be conducted for all new influenza vaccines. 
Enhanced monitoring of vaccine safety and efficacy is needed. It is an open 
question whether neuraminidase-specific antibody responses need to be analysed. 
While anti-HA antibodies are known to inhibit viral infection and replication, 
neuraminidase antibodies (anti-NA) were discovered to play a role in the 
prevention of a clinical disease (Murphy, Kasel and Chanock, 1972). Identifying 
the role of anti-NA response to vaccination is also important, even though the 
quantity of NA protein in current influenza vaccines has not been standardized. It 
has been reported that in the absence of well-matching anti-HA antibodies, NA-
specific antibodies can still provide protection against clinical influenza illness 
(Marcelin, Sandbulte and Webby, 2012; Jagadesh et al., 2016). Different 
techniques may be applied to quantitate NA. Accelerated Viral Inhibition with NA 
(AVINA) assay was shown to be advantageous to predict vaccine efficacy and the 
assay is relatively simple to perform (Hassantoufighi et al., 2010). A great 
advantage of the assay is its potential to simultaneously quantify hemagglutinin 
and neuraminidase-inhibiting antibody responses. However, the most used 
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technique to measure NA-specific antibodies is an Enzyme-Linked lectin Assay 
(ELLA) (Lambré et al., 1990). 
2.2 Multiplex technologies  
The onset of multiplex era opens up new research possibilities. To date, numerous 
multiplex assays used in diagnostics, cohort screening and research setups have 
been described (Engin, 2019). Multiplex assays overcome the limitations of 
conventional serological assays enabling simultaneous detection of multiple 
analytes in a single sample. High sample throughput, simultaneous detection of 
several analytes, low cost and the requirement of small sample volumes make 
multiplex immunoassays well suitable for testing large numbers of samples from 
clinical vaccine trials and serosurveillance studies. Multiplex technologies can be 
divided into two main categories of bead-based and microarray assays, described in 
the following sections. 
2.2.1 Bead-based multiplex assays 
Bead-based multiplex assays utilise polystyrene (Moss et al., 2004), glass 
(Ostendorff et al., 2013) or magnetic sets of beads with different fluorescent codes  
(Zhu, Duan and Publicover, 2010). The beads are coated with either specific 
antibodies or antigens. A single sample can be analysed against multiple analytes 
with multiple sets of color-coded beads. There are two major types of bead-based 
assays: Luminex and cytometric bead assays (CBA) (Ayling, Vedhara and 
Fairclough, 2018). The CBA system from BD Biosciences 
(www.bdbiosciences.com) does not require expensive equipment. A standard 
clinical flow cytometric device can be used to read the results. However, CBA uses 
one fluorescent colour per bead set that limits the number of measured analytes. 
Luminex multi-analyte profiling (xMAP) is a customizable commercial technology 
from Luminex which has a broader multiplex capacity (www.luminexcorp.com; 
later referred as Luminex; based on original publications of (Dunbar and Li, 2010; 
Angeloni et al., 2014). Up to 100 analytes per well in a 96-well microtiter plate can 
be analysed simultaneously by Luminex. The procedures of all bead-based 
multiplex assays are similar and rely on bead sets coded with fluorescent dyes and 
flow cytometry.  
The principle of the Luminex multiplex assay is shown in Figure 4. The 
specific antigen of interest is conjugated onto the surface of polystyrene beads.  
Each well in 96-well microtiter plate contains multiple bead sets with different 
fluorescent signatures and antigens. A serum sample is added to a mixture of bead 
sets and antibodies bind to their specific antigens. The detection is based on 
Review of the literature 
 27 
biotinylated anti-species antibodies and phycoerythrin (PE)-conjugated streptavidin 
which binds to biotin. Dual-laser flow-based detection instrument, such as the 
Luminex® 100™ analyser, is used to read signals for each bead set. One laser 
classifies the beads on the basis of their fluorescent signatures and determines to 
which antigen antibodies are bound. PE-derived signal is determined by a second 
laser. The signal intensity is proportional to the amount of bound antibodies.  
 
Figure 4.  The principle of Luminex polystyrene bead-based multiplex assay.   
Similar to all multiplex assays, the main advantage of bead-based assays is the 
ability to measure simultaneously multiple analytes and antibody isotypes. The 
assays require smaller sample volumes and they are highly efficient in terms of 
time and costs. The assays are widely used in different fields of biosciences, such 
as studies on inflammation, diabetes, immunology and virology (S. X. Leng et al., 
2008; Martins, Litwin and Hill, 2008; Purohit, Sharma and She, 2015). The bead-
based multiplex assay detection systems are based on fluorescent signals and have 
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a large dynamic range compared to ELISAs. Currently, magnetic bead-based 
immunoassays displace polystyrene bead-based assays. Magnetic bead-based 
assays enable separation analytes during washing steps which improves the ability 
for automatization (Houser, 2012).  
Good correlations between ELISA and bead-based multiplex assays have been 
reported (Khan et al., 2004; Elshal and Mccoy, 2006). Multiplex fluorescent 
microsphere immunoassay for the determination of antibodies e.g. against three 
Epstein-Barr virus (EBV) antigens showed a good correlation with ELISA (83.8%-
92.8%%) and even better correlation with IFA (92.8%-98.1%) (Martins, Litwin 
and Hill, 2008). The degree of correlation between bead-based multiplex assays 
and ELISA depends on how the comparisons are made and whether similar 
reporter antibodies and diluents are used (Elshal and Mccoy, 2006). Bead-based 
multiplex assays results have been reported to be much higher than ELISA values 
(Ray et al., 2005). This can be explained by the fact that in bead-based multiplex 
assays all reactions take place in solution, while in traditional ELISA 
antigens/antibodies are bound to solid-phase plastic. However, cross-reactions are 
possible and potential biomolecule interactions in the same assay solution must be 
considered. There are, however, some technical problems with multiplex assays 
and caution with the interpretation of the results is needed when compared with 
ELISA data.  
The total costs of multiplex assays are lower if compared to the costs of 
separate ELISA assays used to obtain the same amount of data. Even though the 
multiplex technology is more cost effective, it requires an initial investment in 
expensive equipment and software. "For example, Luminex technology-based 
systems require a dedicated analyser with a price tag of ca. $60,000 and the price 
of multiplexed ELISA systems (Randox Laboratories and MesoScale Discovery) 
range from $90,000 to $140,000."(Sean X Leng et al., 2008). From the other side, 
despite the fast growing field of multiplex assays, single analyte detection tests 
could stay in use for decades. Current multiplex assays cannot be tailored to the 
individual patient. Clinicians or patients might desire to be screened only for one or 
a few targets, but with the multiplex systems they are forced to be screened against 
all analytes included in the multiplex assays.  
2.2.2 Microarray-based multiplex assays 
The multiplex chip or microarray-based assays have been widely used in 
proteomics to study protein functions and interactions, and in genetic research to 
examine the expression of multiple genes (Schena et al., 1995). Microarrays 
consist of biomolecules immobilized to a solid phase, usually plastic, glass, 
silicone or nylon (Pastinen, 2000; Sachse et al., 2005; Cretich et al., 2006). 
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Immobilized biomolecules can be oligonucleotides, PCR products, proteins, 
peptides, carbohydrates, or other small molecules. Many studies have demonstrated 
microarray assays to be a useful tool in biochemical research. Most microarrays are 
based on nucleic acids or proteins. In infectious disease studies, nucleic acid-based 
microarrays are used to identify microbial pathogens whereas protein microarrays 
are used to identify specific antibodies against different pathogens. Protein 
microarrays may have either antibodies or antigens immobilized in an array format. 
Protein microarray assays have shown a broad application range: testing of 
antibody specificity, studies of protein function, identification of the protein targets 
of small molecules, screening for protein-protein interactions, identification of 
antigenic proteins and immune responses to them (Michaud et al., 2003; Qiu et al., 
2005; Selvarajah et al., 2014; Negm et al., 2015).  
The first microarrays detecting viral genetic material were described in the 
early 2000s (Chizhikov et al., 2002; Wilson et al., 2002; Sengupta et al., 2003). 
Nucleic acid microarray methods are based on oligonucleotides which capture PCR 
products and use different visualization approaches (Wang et al., 2002; Lovmar et 
al., 2003; Boriskin et al., 2004; Albrecht et al., 2006). Multiple viral antigens can 
be detected simultaneously from a single sample by microarray assays. This makes 
the microarray technology very well suitable tool for large-scale screening 
purposes. Presently, microarray assays are widely used in virology to detect and 
genotype influenza-, RSV-, adeno-, corona-, flavi-, zoonotic, rota-, noro-, astro-, 
entero-, papilloma- , hepatitis and other viruses (Gemignani et al., 2004; Coiras et 
al., 2005; Nordström et al., 2005; Chou et al., 2006; Gauthier et al., 2010; Díaz-
Badillo et al., 2014; Wang et al., 2017; Erickson et al., 2018; Kim et al., 2018; 
Xiao et al., 2019; Nybond et al., 2019). 
Currently, many nucleic acid-based microarray technologies are being 
developed. The development of new primers facilitates the simultaneous detection 
of a wide range of multiple pathogens and subtypes. For instance, Takizawa et al., 
(2013) developed a simultaneous pathogen detection system for viruses, such as 
human hepatitis C virus (HCV), human hepatitis B virus (HBV), human parvovirus 
B19 (PVB19), and West Nile virus (WNV), and human immunodeficiency virus 
(HIV) (Takizawa et al., 2013). Chemiluminescence (CL) detection oligonucleotide 
microarray was developed for the detection and genotyping of different strains of 
influenza A and B viruses, including avian influenza A H5N1 and H7N9 subtypes 
(Zhang et al., 2016). The authors reported 91.1 % sensitivity of the microarray as 
compared to real-time PCR.  
Several commercial microarray technologies for the detection of virus 
infections are available. Clart PneumoVir and Clart FluAVir kits (Genomica, 
Madrid, Spain) are commercial technologies allowing simultaneous detection and 
identification of 21 different types and subtypes of human respiratory viruses 
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(influenza A/H1N1 and A/H3N2 viruses, influenza B and C viruses, RSV A and B, 
PIV-1, PIV-2, PIV-3, PIV-4, PIV-4 A and B, coronavirus E-229, HRVs, HMPV A 
and B, HBoV, adenoviruses, and enterovirus species B). Renois et al., (2010) 
described a study where they compared generic real-time RT-PCR assay for the 
detection of influenza A viruses with commercially available microarray assays 
(Renois et al., 2010). The study confirmed that microarray technology allows a 
rapid and accurate detection of viral nucleic acids and it has a great potential for 
routine virological diagnosis.   
DNA microarrays are capable of simultaneously detect hundreds of viruses. 
The first viral microarray was described in 1999 for human cytomegalovirus  
(Chambers et al., 1999). In 2002, Wang et al. described a microarray assay for the 
detection of 140 viruses (Wang et al., 2002). Such high throughput multiplex 
technologies are important to provide not only epidemiological and virological 
information but also the opportunity to understand the emergence of new virus 
strains. Furthermore, Wang et al. (2003) designed a DNA microarray which is able 
to identify and characterise existing and novel viruses. They combined array 
hybridization with direct sequencing of viral genomes. With the established 
methodology a previously uncharacterized coronavirus was discovered (Wang et 
al., 2003). Chou et al., (2006) designed a microarray for identification of emerging 
viruses at genus level using the principle of conserved probe design. The detection 
is based on the finding that highly similar sequences can hybridize with all viruses 
of a particular genus but not with other genera viruses (Chou et al., 2006). 
2.2.3 Serological multiplex microarray assays 
Recently, multiplex protein microarrays have become widely used in serology to 
detect antibodies against multiple microbial antigens. This type of microarray is 
called antigen microarrays. They are widely used in research to measure antibody 
responses against different microbes or their structural components and to profile 
antibody responses to different proteins in order to evaluate promising candidates 
for future subunit vaccines and/or diagnostic antigens. The generalized principle of 
antigen microarrays is shown in Figure 5.  
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Figure 5.  Schematic principle of multiplex antigen microarray immunoassays.  
Tiny spots of antigens of interest and protein controls are printed onto a surface of 
a functionalised glass slide (Selvarajah et al., 2014) or plastic wells of a microtiter 
plate (Gehring et al., 2008). The spots are printed by a robotic array printer 
creating spots <200 µm in diameter. Then blocking solution is added to prevent 
further nonspecific binding. Antibodies from diluted serum samples bind to 
specific antigen spots and positive control spots. After washing, labelled anti-
human antibodies are added. Typically, the detection system is based on 
fluorescence (Andrew D. Livingston et al., 2005). Detection antibodies are labelled 
with a small molecule biotin that can be recognized by the protein streptavidin 
(Ayling, Vedhara and Fairclough, 2018). Then a fluorescent dye-conjugated 
streptavidin is added and it binds with high specificity to the biotinylated antibody. 
Upon excitation with a laser, fluorescence is generated. The slides or plates are 
read by a laser scanner. Antibody responses are determined based on antigen spots 
position. Microarray data are pre-processed with specially designed software that 
finds spots and counts average signal intensity in a pre-defined spot area. As a rule, 
all data are filtered with pre-defined criteria and aberrant spots are removed. 
Obtained fluorescence intensity values are proportional to the amount of detected 
antibodies. The antibody concentration is quantified based on a standard curve.  
Microarray assays are frequently called ”miniaturised ELISAs”. Compared 
with traditional ELISAs, multiplex microarray immunoassays have a number of 
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advantages including: 1) simultaneous detection of multiple analytes; 2) 
simultaneous detection of different antibody isotypes; 3) requirement of small 
sample volumes; 4) time and cost efficiency; 5) accurate detection of different 
antibodies with a wide dynamic range. The last advantage is especially important 
in vaccine studies where high levels of antigen-specific antibodies are found in 
post-vaccination samples. ELISA has a quite narrow dynamic range and multiple 
sample dilutions may be need to be analysed. A limiting factor of the microarray 
assays is the requirement of expensive machinery. In addition, aberrant spots are 
known to occur during array printing stage. These spots are typically of inadequate 
morphology including size and shape. In addition, the purity of the protein, its 
native conformation after immobilization, and storage conditions may lead to 
technical variation in the microarray assay. Thus, the assay requires multiple 
internal controls and good expertise of the staff running the assays.  
A wide range of microarray immunoassays for detection of antibodies against 
different viruses, such as herpesviruses, measles, rubella, mumps, HIV, Epstein-
Barr virus, cytomegalovirus, coronavirus, vaccinia virus and for five hepatitis 
viruses (HAV, HBV, HCV, HDV and HEV) in human sera have been already 
developed (Mezzasoma et al., 2002; Davies et al., 2005; Qiu et al., 2005; Xu et al., 
2007; Kwon et al., 2008; Jääskeläinen et al., 2009; Feron et al., 2013; Sivakumar et 
al., 2013). Microarrays can be set up with virus recombinant proteins or whole 
viruses as antigens. Some microarray assays have even been reported to be more 
specific than ELISAs. For instance, a sol-gel-based protein microarray developed 
for the detection of hepatitis C virus antibodies showed 98.78% specificity whereas 
ELISA showed 81.71% (Kwon et al., 2008). Several influenza virus antibody-
specific multiplex microarray assays have been designed and they have shown a 
great potential in studies for profiling of humoral immune responses to influenza 
viruses and characterization of influenza vaccine induced humoral responses (Gall 
et al., 2009; Koopmans et al., 2012; Desbien et al., 2013; Price et al., 2013; Freidl 
et al., 2014). Influenza virus protein microarrays for measurement of antibody 
responses to influenza A in animals and poultry have been started to be developed 
(Freidl et al., 2014; Meade et al., 2017). A multiplex microarray based on five 
RSV proteins for the determination of antibody levels against RSV was designed 
and it showed a good correlation with microneutralization test (Schepp et al., 
2019). Multiplex microarray assays for simultaneous detection of different 
antibody classes have also been developed. Liu et al., 2013 developed a 
recombinant antigen-based microarray assay for simultaneous detection of IgM and 
IgG antibodies against herpes simplex virus type 1 and 2, cytomegalovirus and 
rhinovirus in a single sample (Liu et al., 2013). For vaccine studies multiplex assay 
have recently been started to be developed. Multiplex poliovirus assay has been 
successfully used in large-scale vaccine studies and the assay showed a great 
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potential as a safe assay without the need to use live polioviruses (Schepp et al., 
2017). A multiplex assay for simultaneous detection of antibodies against hepatitis 
B, Haemophilus influenzae B, diphtheria, tetanus, pertussis rubella, and RSV 
demonstrated its applicability in studying immune responses against common 
childhood vaccines (Itell et al., 2018). 
Antibodies bound to different antigens on the microarray can be detected by 
different methods. In general, multiplex microarray assays are based on either 
chemiluminescent or fluorescent detection systems. Chemiluminescence 
technology has been considered to be more sensitive than chromogenic detection in 
traditional ELISA assays. Multiplex immunoassays employing 
electrochemiluminescence technology are also commercially available, e.g. kits 
from Meso Scale Discovery (www.mesoscale.com). The electric wired microplate 
is coated with specific antibodies. A tag in detection antibodies is excited by an 
electric field. Time-dependent signal decay-related problems are avoided when 
electrochemiluminescence-based assays are used  (Sean X Leng et al., 2008). In 
fluorescence based detection systems a cyanine-labelled secondary antibody are 
commonly used (Lu et al., 2005).  
There has also been a successful development of label-free serological 
microarrays. For instance, a label-free immunoassay for flavivirus detection was 
developed based on a principle of Reflective Phantom Interface (RPI) technology 
(Tagliabue et al., 2017). Arrayed Imaging Reflectometry (AIR) is commonly used 
in such microarray sensors. The detection is based on perturbation of an 
antireflective coating on the surface of a silicon chip when antibody binds to an 
immobilized target antigen. When serum antibody is captured, a film thickening 
gives rise to a signal generation in the form of reflected light. Multiple probe/target 
interactions may be simultaneously monitored without any requirement for 
secondary antibodies or labelling. The amount of antibodies present in a sample is 
quantified proportionally to the reflectance changes. Label-free biosensor 
technique is able to provide quantitative information up to 100 of analytes 
simultaneously.  
Such a label-free optical biosensor based on the AIR detection system was 
developed for analysing immune responses against influenza viruses using a panel 
of recombinant hemagglutinin proteins (Mace et al., 2011). The assay can be 
performed in the field conditions and it demonstrated the capability to dramatically 
simplify influenza surveillance. Another multiplex hemagglutinin microarray based 
on AIR technology also proved to be rapid and sensitive for the detection of 
influenza-specific antibodies in both human and avian serum samples (Bucukovski 
et al., 2015). Serological assessment of influenza exposure in the field is especially 
important when anti-HA antibody titers in avian serum are analysed. Avian species 
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are the primary reservoir of type A influenza viruses and a rapid detection of the 
exposure to avian influenza is needed (Webster, 2002).  
In recent years, microarray technology has been actively developed and 
currently microarray assays are based not only on immobilised nucleic acids and 
proteins but also cells, glycans, and carbohydrates (Andrew D Livingston et al., 
2005). For instance, Rider and co-workers engineered a light-emitting B cell-based 
system which is able to detect pathogens within 3 minutes (Rider et al., 2003).  
2.2.4 Commercially available multiplex immunoassays 
Several planar multiplex microarray assays and bead-based suspension assays are 
commercially available. Most of these assays have not been validated for in vitro 
diagnostics and they are currently available for research use only. The largest 
number of commercially available multiplex assays are designed for studies on 
autoimmunity, allergy and cytokine and chemokine profiling (Tighe et al., 2015). 
However, a substantial proportion of commercial multiplex assays are also 
available for cardiovascular, angiogenesis and infectious disease studies. Table 1 
shows the currently available commercial multiplex assays for serum antibody 
detection in patients with infectious diseases.  
Table 1.  Commercially available multiplex immunoassays for antibody detection suitable for 
infectious disease research and diagnostics  
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Bead-based suspension assays are currently the dominant technology among FDA-
approved multiplex protein assays in clinical settings (Ellington et al., 2010). Bead-
based multiplex assays are based on flow cytometry and easily adaptable for 
automation and for large-scale screening. However, planar microarray 
immunoassays are more affordable as they are relatively inexpensive and simple to 
perform. In addition, planar microarray-based immunoassays are less susceptible to 
cross-reactivity as capture proteins are immobilised on a solid phase (Tighe et al., 
2015). It has been reported that cross-reactivity increases considerably with the 
number of targets in suspension multiplex assays (Pla-Roca et al., 2012). In 
addition, such systems are highly sensitive to changes and inclusion of new 
analytes to the panel requires optimisation of the whole assay.  
Despite the relatively high expenses of currently available commercial systems, 
serological microarrays have the potential to replace some of the presently used 
assays and be used as a fast screening tool in the future. The multiplex techniques 
are likely to be further adapted to fulfil the routine diagnosis criteria of viral 
infections and commercial applicable assays will be available in the nearest future.  
2.3 Selected viruses and antigens for multiplex 
immunoassay 
2.3.1 Respiratory syncytial virus 
The respiratory syncytial virus (RSV) was discovered in 1956 when the virus was 
isolated from chimpanzees (Blount, Morris and Savage, 1956). RSV is a member 
of the Orthopneumovirus genus, of the family Pneumoviridae (Rima et al., 2017). 
The virus is an enveloped, non-segmented virus with a single negative-sense RNA 
genome. The viral genome encodes 11 proteins including three envelope proteins, 
the fusion (F) and the attachment (G) glycoproteins, and a small hydrophobic (SH) 
protein (Borchers et al., 2013). The G protein is responsible for the virus 
attachment on the host cell surface and the F protein participates in cell penetration 
and facilitates transmission between cells by syncytia formation. Antibodies 
targeted against either G or F protein play a major role in protective immunity 
against human RSV (Ascough, Paterson and Chiu, 2018). These antibodies have 
the ability to neutralize virus infectivity. The F protein induces widely cross-
reactive antibody response against different RSV strains, whereas the G protein 
induces neutralizing antibodies that only function against the viruses of the same 
antigenic group. RSV has two major antigenic subgroups A and B. The 
classification is based on antigenic differences detected with monoclonal 
antibodies specific for the G protein. Only 53% of the G protein sequence is 
conserved between RSV A and B groups. Both subgroups co-circulate in the 
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community during the epidemics and either one of subgroup viruses may be 
predominant (Gilca et al., 2006). The evolutionary rate of RSV is relatively slow 
(Tan et al., 2012). Studies on RSV protein sequence variability reported the G 
glycoprotein to be the most variable protein. The attachment protein G has 2 to 
12% sequence variability within the subgroup, whereas other RSV proteins have 0 
to 5% variability between the consensus sequences of type A and type B RSV 
strains (Tan et al., 2013). The mean substitution rates of the RSV A and B 
subgroups are similar, with 7.76 (× 10-4 substitutions/site/year) for RSV-B and 6.47 
(× 10-4 substitutions/site/year) for RSV-A (Tan et al., 2013) 
RSV causes substantial epidemics with 1-2 epidemic periods each year all over 
the world (Haynes et al., 2013). When suspected, RSV infection may be confirmed 
using a number of diagnostic methods such as RT-PCR, rapid antigen detection 
tests (RADT), ELISA, IFA and viral culture. Several RADTs for RSV are available 
in the form of immunochromatographic tests, enzyme immunoassays and optical 
immunoassays with varying (70% to 90%) sensitivity (Prendergast and Papenburg, 
2013). RSV infection poses a high risk for severe disease in infants during the first 
year of life (Weisman L., 2003). It has been proved to be the most important cause 
of pneumonia and bronchiolitis in infants and young children (Piedimonte and 
Perez, 2014). Approximately, 1~3% of children under 1 year of age are 
hospitalized due to RSV infection (Leader and Kohlhase, 2002). The peak 
incidence is in children under 1 year of age, but RSV infection also causes a 
substantial disease burden in children one to three years of age (Hall et al., 2009). 
RSV is associated with higher rates of outpatient care visits and hospitalizations in 
young children compared to that caused by influenza infection (Bourgeois et al., 
2009). Generally, all children older than 3 years of age have experienced one or 
more RSV infections (Ogra, 2004). The study by Glezen et al., (1986) showed that 
two-thirds of infants are infected during their first year of life, practically all 
children are infected by the age of 2 years and 76% of children are reinfected 
during the second year of life (W P Glezen et al., 1986). Primary RSV infection 
causes cold-like symptoms including fever, runny nose, cough, wheezing and 
tachypnea (Eiland, 2009). Acute otitis media (AOM) is a common complication of 
RSV respiratory infection. RSV is the most common virus associated with AOM as 
it complicates about 50% of the cases (Patel et al., 2007). The symptoms can 
progress to bronchiolitis or pneumonia in 25-40% of cases and even cause deaths 
(Shay et al., 2001; Thompson, 2003; Zhou et al., 2012). RSV coinfection with 
other respiratory viruses, such as rhinovirus and metapneumovirus is known to 
occur frequently and the coinfection increases the risk of complications (Calvo et 
al., 2015). Very severe RSV infection can sometimes lead to long-term 
complications including the development of wheezing and asthma later in life 
(Welliver, 1998; Carroll et al., 2009). However, in the majority of cases the 
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recovery from RSV infection is complete. In older children and adults the infection 
symptoms are relatively mild.  
RSV is a pathogen with an exceptionally high rate of reinfections and those 
may occur throughout the life and the same RSV serotype can re-infect both 
children and adults. Reinfection is suspected to occur because infection does not 
induce complete long-lasting protective immunity. A study on the correlation 
between the age and susceptibility to RSV infections demonstrated a lower risk of 
severe disease with increasing age but no protection from reinfections (Ohuma et 
al., 2012). RSV infection normally induces host immune responses including the 
activation of both humoral and cell-mediated immunity. Anti-RSV IgG levels play 
an important role in the protection against subsequent infections (Roca et al., 
2002). Generally, immune response to a primary infection is relatively weak but in 
reinfection(s) a significant booster effect is observed in serum. A study by Welliver 
et. al. published in 1980 on the kinetics of class-specific antibody responses to 
primary and secondary RSV infection showed that anti-RSV antibodies wane 
relatively rapidly after a primary infection. IgG antibodies were at a low level or 
absent one year after the primary infection (Welliver et al., 1980). Another study 
also reported that a rapid antibody decline after a primary RSV infection seems to 
facilitate repeated infections (C J Sande et al., 2013). This study showed that in 
young children neutralizing antibodies against RSV declined to pre-infection levels 
within 3 months after the infection. Second RSV infection induces boosted immune 
response with higher antibody levels in all three immunoglobulin classes and the 
antibodies persist for longer periods after reinfection. RSV studies suggest that a 
basic level of antibodies is needed for the protection against lower respiratory tract 
infection. The effect of aging was demonstrated to reduce antibody production in 
response to RSV infection. A study comparing neutralizing antibodies to RSV in 
healthy young individuals (20–60 years age) and in elderly (>80 years of age) 
showed that only 36.21% of aged individuals had RSV neutralizing antibodies 
compared with 92.5% in the youngest group (Terrosi et al., 2009). In general, 
adaptive immune response to respiratory virus infections are known to decrease 
with age and elderly people are more susceptible to RSV infection and disease 
complications (Fulton and Varga, 2009). Also very young children and 
immunosuppressed individuals, show reduced ability to mount a protective 
immunity to RSV. A study in cotton rats showed that old cotton rats are cured from 
RSV infection slower than the young ones (Guichelaar et al., 2014). Reduced virus 
clearance at the older age was found in the rat lungs and in the upper airways. 
However, the relationship between antibody levels induced by RSV in humans and 
age is still a subject of speculation.  
Presently, there is no good specific antiviral treatment for the RSV infection 
apart from antibodies. The treatment for severe RSV infection is usually limited to 
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supportive care. At hospital, severe RSV disease is managed by oxygen 
supplementation, continuous positive airway pressure and mechanical ventilation. 
Ribavirin is the only approved drug for the treatment of severe RSV (Krilov, 
2011). However, due to conflicting data on efficacy and side effects of the drug, 
the use of ribavirin is very limited (Mazur et al., 2015; Drysdale, Green and Sande, 
2016). Humanized monoclonal antibody product Synagis® (palivizumab) is 
available for prophylaxis against severe disease caused by RSV infection 
(Welliver, 1998). However, in view of high costs it is warranted only in selected 
high risk and prematurely born infants. RSV vaccines would be highly desirable 
but currently they are still in the developmental phase. A formalin inactivated 
crude, whole virus vaccine was tried in 1960, but this vaccine failed to produce 
protective immunity and vaccination led to a more severe disease during 
subsequent natural infection. Despite intensive efforts to design an effective RSV 
vaccine, a licensed vaccine is still not available (Piedra, 2003). Annual vaccination 
against RSV would likely be needed despite the genetically stable virus because 
serum antibodies wane rapidly. 
2.3.2 Influenza viruses 
Influenza viruses are classified into four types, A, B, C and D viruses (Long et al., 
2019). Influenza B and C are human viruses and influenza D infects only some 
animals. A wide variety of host species are infected by influenza A viruses. The 
dominant influenza A virus hosts are humans, birds, and pigs (Mostafa et al., 
2018). Influenza A (IAV) is the most important member of the influenza virus 
group and IAV causes worldwide yearly epidemics and occasional pandemics. 
Influenza A virus has a remarkable capacity to change its antigenic structures (Das 
et al., 2013). Animal influenza A viruses, especially avian influenza may overcome 
species barriers and initiate new pandemic in humans. Due to susceptibility of 
influenza A viruses to mutations, animal influenza may establish occasional 
interactions with humans at any time. If a novel animal virus adapts to a human 
host, it may become transmissible between the humans which may result in the 
emergence of a new pandemic virus. Avian influenza is usually asymptomatic in 
birds but it may be dangerous and highly pathogenic when transmitted to another 
species. There has been documented cases of human infections caused by avian 
influenza viruses of H5, H6, H7, H9 and H10 subtypes (Long et al., 2019).  
Influenza viruses are divided into subtypes according to antigenic differences 
of the viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) 
(Sautto, Kirchenbaum and Ross, 2018). These antigenic differences take place 
either by point mutations and short deletions or insertions leading to changes in the 
amino acid composition of the antigenic determinants of HA or NA proteins. This 
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phenomenon is called the antigenic drift. However, influenza A viruses evolve also 
by a genetic reassortment called antigenic shift, i.e. where a whole segment of the 
genome is transferred from one virus subtype to another. The antigenic shift has 
not been observed in influenza B and C viruses because they infect only humans 
(Jernigan and Cox, 2013) and these viruses tend to show slower antigenic variation 
compared to influenza A viruses. Influenza A virus is an enveloped virus with a 
diameter of 100-150 nm (Bouvier and Palese, 2008). The envelope is composed of 
HA and NA molecules embedded in a lipid bilayer derived from the plasma 
membrane of the host cell. Underneath the membrane there is a protein layer that 
consists of matrix protein (M). Nucleoprotein (NP) is the major nucleocapsid 
protein that covers the segmented RNA genome (8 segments) of the virus. Viral 
polymerase proteins, PB2, PB1 and PA are also components of the viral 
nucleocapsid structures. Amino acid changes in the major antigenic regions may 
alter the antigenic structure of the hemagglutinin giving rise to a new virus variant 
(antigenic drift) (Das et al., 2013).  
There is 25-40% conservation in the amino acid sequences between influenza 
A and B virus HAs. Influenza virus HA binds to sialic acid receptors onto host cell 
surface (Hensley et al., 2009). Species-specific susceptibility to influenza virus 
infection is determined by the structure of these receptors and the ability of virus 
HA to attach to them. The receptor binding specificity is a key determinant of the 
virus transmissibility (Tumpey et al., 2005). Antibodies against HA can prevent the 
attachment of the virus onto cellular receptors or they can prevent the fusion of 
viral and cellular membranes. The extent of HA glycosylation and its changes are 
known to be important in the ability IAV to cross-infect different species (Herfst et 
al., 2012). In NA the antigenic drift and antigenic shift also occur and considerable 
variation between the strains is observed. NA catalyses the cleavage of terminal 
sialic acids of the sugar residues of cellular glycoproteins enabling the release of 
progeny virions (Matrosovich et al., 2004). Antibodies against NA are known to 
give some protection, but they cannot fully neutralise the virus.  
Currently, several different approaches are available for diagnosis of influenza 
infections, including viral culture, immunofluorescence assays, serological assays, 
nucleic acid amplification tests and immunochromatography-based rapid 
diagnostic tests (Vemula et al., 2016). However, Centres for Disease Control and 
Prevention (CDC) recommend diagnosing influenza infections only by nucleic acid 
amplification tests (e.g. reverse transcription-polymerase chain reaction (RT-PCR) 
test) and antigen detection tests (including rapid influenza diagnostic tests (IRDT) 
and immunofluorescence assays) in clinical settings (Centres for Disease Control 
and Prevention (CDC) Seasonal Influenza (Flu), 2016). Influenza vaccine 
responses are usually analysed by HI, VN, and SRH tests. High mutation rates 
allow influenza viruses to escape from host immune responses. Therefore, the 
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effectiveness of influenza vaccines are relatively low compared to that of other 
viral vaccines. Influenza vaccines are annually reformulated in order to cope with 
the changes observed in seasonal circulating strains. To date, whole inactivated 
virus vaccines, split virus and subunit vaccines, live-attenuated and recombinant 
HA-based influenza virus vaccines have been used (Krammer, 2019). All of these 
vaccines are required to be reformulated each year to match well with the 
antigenicity of circulating viruses. Serum antibody response to a natural influenza 
infection is usually strong, the response is HA and NA-specific and very long-lived 
or even lifelong (Krammer, 2019). Split virus or subunit and recombinant HA-
based vaccines induce strong serum antibody response but weak or undetectable 
mucosal antibody response and the persistence of vaccine-induced antibodies is 
often of short duration (Wong and Webby, 2013). In addition, the strength of 
individual responses to influenza vaccine antigens varies tremendously. Despite 
major efforts to control influenza infections, the efficacy and effectiveness of 
seasonal vaccines in children have varied a lot (Osterholm et al., 2012; Jefferson et 
al., 2018). There are great efforts to design a broadly protective influenza vaccine, 
so called universal influenza vaccine, to avoid the need of annual influenza 
vaccinations (Yamayoshi and Kawaoka, 2019). Currently, universal influenza virus 
vaccines based on original antigenic sin phenomenon are in clinical trials 
(Krammer, 2019). 
2.3.3 Influenza 2009 pandemic vaccine antigen 
During the last one hundred years influenza A viruses have caused five pandemics. 
The swine-origin influenza A 2009 virus likely originated from Mexico and it 
spread all over the world causing the most recent pandemic. Influenza A H1N1 
subtype virus have caused three pandemics: in 1918-1920, 1977-1979 and in 2009-
2010 (Allwinn et al., 2010). H2N2 and H3N2 subtypes caused the 1957 and 1968 
pandemics, respectively (Kilbourne, 2006). The latest pandemic was caused by an 
H1N1 reassortant virus that emerged from swine and it was relatively mild with an 
estimated mortality of ca. 0.02% (Van Kerkhove et al., 2013). However, due to 
ongoing virus evolution there is a threat of a more severe pandemic in the future as 
it was with “spanish flu” in 1918-1920. A new variant of emerged pandemic 
influenza A virus in 2009 had substantial antigenic differences in relation to the 
seasonally circulating H1N1 viruses (Zhang, Song and Wang, 2012). Although it 
was shown that elderly people had some cross-reacting antibodies, most of the 
population had no herd immunity against the new emerged influenza (Hancock et 
al., 2009; Ledford, 2009). In Finland, influenza A (H1N1)pdm09 viruses 
predominated during the influenza seasons 2009-2010, 2012-2013, 2013-2014 and 
2015-2016 (Lyytikäinen et al., 2011). Influenza A (H1N1)pdm09 virus displaced 
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the previous seasonal H1N1 virus and currently H1N1 and H3N2 viruses co-
circulate together with two lineages of influenza B viruses and cause seasonal 
epidemics.  
In 2009, seasonal H1N1 viruses and pandemic H1N1 virus had high antigenic 
mismatch (Saxena et al., 2009), which allowed the virus to spread rapidly in the 
whole population. When the pandemic was declared by WHO, the production of 
seasonal vaccines was replaced by the production of the pandemic vaccine 
(Johansen, Pfeifer and Salisbury, 2018). To prevent the spread of the pandemic, 
Pandemrix™ vaccine was used in Europe in 2009-2011 (European centre for 
disease prevention and control, 2013). Pandemrix is an AS03-adjuvanted influenza 
A (H1N1)pdm09 vaccine produced by GlaxoSmithKlein, Rixenart, Belgium (Tsai, 
2011). In 20 countries more than 30.5 million people were vaccinated. A similar 
AS03-adjuvanted influenza A (H1N1)pdm09 vaccine (Arepanrix) against 2009 
pandemic influenza was produced in Canada where it was used locally (Ahmed and 
Steinman, 2016). There were also other nonadjuvanted vaccines developed and 
produced to prevent the pandemic. Pandemrix vaccine was highly immunogenic 
and effective against infections caused by this virus (Syrjänen et al., 2014). Several 
studies reported that the vaccine was most effective in children and adults aged 18–
64 years (Lansbury et al., 2017). Overall, the vaccination has successfully 
prevented influenza-related hospitalization. However, there were increased cases of 
narcolepsy in children reported and associated with the pandemic influenza 
vaccination in some European countries (Jefferson et al., 2018). The possible 
biological mechanism in Pandemrix-associated narcolepsy has remained 
unresolved.  
2.3.4 Human adenoviruses 
Human adenoviruses (hAdVs) belong to the genus Mastadenovirus in the 
Adenoviridae family (Davison, Benko and Harrach, 2003). HAdVs are divided into 
seven sub-groups (HAdV-A to G) based on phylogenetic analysis, genomic 
organization, growth characteristics and oncogenicity (Robinson et al., 2013). 
Currently, HAdVs account for over 70 different genotypes (Radke and Cook, 
2018). However, most human infections are associated with only one third of these 
viruses. HAdVs are icosahedral, non-enveloped, linear double-stranded DNA 
viruses. Hexon (n=240) and penton (n=12) proteins constitute the two major outer 
virion proteins. The penton and hexon proteins define the hAdV serotype. Most 
detection methods and the typing of the viruses are based on conserved (C1 to C4) 
and variable (V1 to V3) sequences of the hexon gene (Biere and Schweiger, 2010).  
Adenoviruses periodically cause global infection outbreaks. Clinical 
manifestations of the infection depend on the HAdVs subgroup. HAdVs can cause 
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conjunctival, upper and lower respiratory tract and gastrointestinal tract infections 
(Radke and Cook, 2018). The virus is known to cause persistent infections in 
humans that can last for months or years and severe disease forms are seen in 
immunocompromised patients (Lion, 2014). Occasionally, the viruses can cause 
disease in the liver, urinary tracts, pancreas or in the central nervous system in 
immunocompromised individuals (Niemann et al., 1993). The most common 
HAdV infections are keratoconjunctivitis and upper or lower respiratory tract 
infections. HAdV can cause large and prolonged outbreaks as the virus is 
extremely resistant to different physical factors and chemical agents and the virus 
may remain viable for many days (Radke and Cook, 2018). Respiratory tract 
infections caused by HAdV are usually mild and self-limiting in healthy 
individuals. However, newly emerged hHAdV with viral mutations are known to 
cause severe respiratory infections leading to pneumonia and rarely to acute 
respiratory distress syndrome (ARDS) (Cook and Radke, 2017). Respiratory tract 
infections are usually caused by adenovirus species C and B1 in infants and young 
children and by species E in military recruits.  
The transmission of adenovirus diseases varies from sporadic to epidemic. A 
large number of completely asymptomatic adenovirus infections have been 
documented (Ketler A, Hall CE, Fox JP, Elveback L, 1969). Most infections in 
young children have been reported to be transmitted through fecal-oral route. 
Adenoviruses account for about 5% to 10% of the respiratory infections in young 
children. The usual symptoms include nasal congestion, fever, chills, headache, 
coryza and cough. According to the study of Cooper et al., (2000), children of less 
than 5 years of age was the largest group suffering from adenovirus infections. 
Among adenovirus infected individuals 61% were under 5 years of age, 6% were 5 
to 15 year-olds and 24% were adults (Cooper et al., 2000). In about 10% of 
infected children adenovirus infection may lead to pneumonia. 
The molecular basis for adenovirus pathogenesis and differences in disease 
severity among adenovirus subtypes are still unresolved. Serological surveys are 
crucial for studies on adenovirus epidemiology. Serological studies estimate the 
adenovirus seroprevalence and determine the most prevalent serotypes (Ludwig et 
al., 1998; Mast et al., 2010). Predominant subtypes differ between countries but the 
most commonly circulated adenovirus subtypes are HAdV-C1, -C2, -C5, -B3, -B7, 
-B21, -E4, and -F413 (Lion, 2014). In children, antibodies against HAdV-C1, -C2, 
-C5 subtypes are the most common ones and antibody prevalence varies from 40% 
to 60% in children (Brandt et al., 1969). Respiratory infections caused by 
adenovirus are common among military personnel. These infections can effectively 
be controlled by vaccination with oral enteric-coated and live vaccines against Ad4 
and Ad7  (Top et al., 1971). Although the adenovirus vaccines are effectively used 
in the military, they are not licensed for administration for the general population 
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and therefore the vaccines cannot be used for susceptible children. In the mid-
1990s, the vaccine production was stopped which lead to increased hAdV 
outbreaks in the military. In 2011, when vaccination in military was restarted, 
adenovirus disease rates dramatically decreased again (Hoke and Snyder, 2013).  
Many adenovirus infections are indistinguishable from other respiratory virus 
infections or even from some bacterial infections. To identify hAdV infections, 
RT-PCR, viral isolation, detection of adenovirus antigens or nucleic acid from 
clinical samples is carried out. ELISA is the most commonly used method to detect 
antibody responses to adenovirus. For instance, anti-hAdV antibodies are analysed 
by ELISA based on a panel of bacterially expressed adenovirus proteins (Bauer et 
al., 2005). There is need for new adenovirus tests for better surveillance of the 
infections and genotyping of the viruses identified in different disease spectra. 
Additionally, there is an increasing interest on adenoviruses used as vectors for the 
delivery of therapeutic proteins to humans e.g. in the treatment of cancer (Wold 
and Toth, 2014).  
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 Aims of the Study 
The overall aim of the study was to develop a novel multiplex microarray 
immunoassay (MAIA) for simultaneous detection of IgM and IgG antibodies 
against multiple viral antigens for large-scale serological and vaccine studies.  
We intended to develop an assay that requires less serum and is less time and 
labour consuming as compared to traditional enzyme immunoassay, for 
determination of serum antibodies against RSV, adenovirus hexon protein, IAV 
H1N1, IAV H3N2, IAV H1N1 pdm09 vaccine ag, IBV Victoria and IBV 
Yamagata. The technology has a strong potential to improve the survey of infection 
diseases and vaccine immunity studies. To demonstrate the functionality of MAIA 
we carried out a large-scale serological study and estimated respiratory infection 
disease burden in early childhood with the established method. We also studied 
influenza vaccine-induced immune responses in a cohort of adults by three 
different methods (HI, EIA, and MAIA) in order to demonstrate the feasibility of 
MAIA in vaccine immunity studies. 
 
The specific research objectives were: 
1. To develop a multiplex antigen-based microarray assay for rapid and 
simultaneous detection of antibodies against multiple viral antigens 
2. To follow-up RSV, adenovirus and influenza specific immunity in 
response to natural infection and vaccination with the newly established 
microarray method 
3. To identify RSV, adenovirus and influenza infection, re-infection rates 
and the duration of protective immunity in early childhood 
4. To develop a multiplex microarray immunoassay for the simultaneous 
detection of IgM and IgG antibodies against influenza A virus antigens  
5. To estimate influenza A vaccine induced immunity with the established 
method and test the suitability of the novel method for diagnostic and 
research purposes 
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 Materials and methods 
4.1 Reagents and samples 
4.1.1 Clinical specimens (I-III) 
In Study I-II child serum specimens were used for serological follow-up of 
respiratory infections by in-house EIA and MAIA. The samples were collected 
from children participating in a birth-cohort study, called the Steps to the Healthy 
Development and Well-being of Children (i.e. the STEPS study) (Lagstrom et al., 
2013). Children (n=1827) born in the Hospital District of Southwest Finland 
between 2008 to 2010 were recruited. The samples were collected and tested with 
the informed consent of the parents. Children were followed-up from birth until 3 
years of age. Annually serum samples were collected from each individual at ages 
13, 24 and 36 months. The sera were stored frozen at   ̶80°C until tested.  
A subgroup of children was followed more intensively until the age of 2 years. 
Within this cohort, 4728 nasal swabs from 876 children were collected during 
acute symptoms of respiratory infection episodes and when the infection was 
considered significant and required the attention of a study nurse or a doctor. Nasal 
swabs from the children were collected either by trained parents at home or during 
the study clinic visit. Also, 2270 nasal swab samples were taken at scheduled study 
clinic visits at 2, 13 and 24 months of age regardless of respiratory illness 
symptoms. The samples were stored at  ̶ 80°C. Respiratory pathogens were 
detected by PCR.  
In Study I, we have analysed a series of three serum specimens, collected at 13, 
24 and 36 months of age from a total of 291 children. The samples were analysed 
for anti-RSV and anti-IAV H1N1 vaccine antigen IgG by in-house EIA. From the 
studied group, 186 children had symptoms of acute respiratory infection and their 
nasal swab samples were analysed by PCR. 
In Study II we tested a larger amount of child serum samples against seven 
virus antigens (RSV, IAV H1N1 vaccine antigen, IAV H1N1, IAV H3N2, IBV 
Victoria, IBV Yamagata, and AdV-C5 hexon protein) simultaneously by MAIA. 
Serum samples collected from 13 months of age (n=768) and 24 months of age 
(n=714) children were analysed. The subgroup that included 13- and 24- months 
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samples from 291 children analysed in Study I by EIA was also tested by MAIA to 
validate the method.  
In Study III an adult cohort of individuals vaccinated with pandemic influenza 
A H1N1 virus vaccine was analysed. A cohort of healthy volunteers was 
vaccinated between January and August 2010 in Tampere, Finland by 
intramuscular injection of PandemrixTM (GlaxoSmithKlein, Rixenart, Belgium) 
vaccine. We collected serum samples at (day 0), four weeks (day 28) and 6 months 
(day 180) after the vaccination and determined anti-IAV H1N1 vaccine antigen 
antibody endpoint titers by three methods: HI, EIA, and MAIA. Virus-specific IgM 
and IgG antibodies were detected by EIA and MAIA in full series of three serum 
samples from 60 individuals.  
4.1.2 RSV and influenza viruses (I-III) 
RSV subgroup A (Randall strain) whole virus was used as an antigen in EIA and 
MAIA in Studies (I-II). The prototype of RSV was initially obtained from the 
Diagnostic Service Unit of the Department of Virology, University of Turku. RSV 
was propagated in Vero cells with Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum, 2mM L-glutamine, 10mM HEPES and 
10 µg/ml gentamicin. The virus was grown for four days until an extensive 
cytopathic effect was observed. RSV antigen collection and purification were 
performed as described previously (Meurman, Waris and Hedman, 1992). 
In Studies (II-III) several influenza A and B viruses were used as antigens in 
MAIA. Influenza virus strains that circulated in Finland during the epidemic 
seasons in 2009-2012 were grown for antigen production. A/Turku/10/2009 
(H1N1), B/Finland/51/2011 Victoria-like lineage and B/Finland/58/2011 
Yamagata-like lineage were propagated in MDCK cells, and A/Finland/208/2012 
(H3N2) was propagated in MDCK-Siat cells with DMEM supplemented with 0,2% 
BSA, 5% TPB, TPCK-Trypsin, HEPES, fungizone and antibiotics. The viruses 
were partially purified through a sucrose cushion pelleting (30% w/w) and 
ultracentrifugation at 25600 rpm for 90 minutes at +4°C (Beckman, rotor SW41). 
All virus antigen pellets were resuspended in a small volume of phosphate-
buffered saline, pH 7.3 (PBS), aliquoted and stored at -60 C̊. Produced and 
partially purified RSV and influenza viruses antigens were further verified by 
Western blotting with Coomassie blue staining. The antigen concentrations were 
measured with PierceTM BCA protein assay kit (Thermo ScientificTM). 
In Study III, H1N1pdm09 (A/California/07/2009 strain; provided by the 
National Institute for Health and Welfare, THL, Finland) vaccine virus was 
propagated in chicken eggs. The virus was utilized as an antigen in the HI test to 
estimate influenza vaccine-induced immunity in the cohort of vaccinated adults. 
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4.1.3 Influenza A H1N1pdm09 vaccine (II-III) 
In Studies (II-III) we used pandemic influenza A H1N1pdm09 vaccine antigen 
(Pandemrix, GlaxoSmithKline Biologicals S.A., Germany). The vaccine is a 
monovalent AS03 adjuvanted vaccine and is composed of split influenza virus, 
inactivated and equivalent to A/California/7/2009 (H1N1)v-like strain (X-179A). 
In Study III the cohort of adult volunteers was vaccinated with one dose of 
H1N1pdm09 Pandemrix vaccine. Also in Studies (II-III) H1N1pdm09 vaccine was 
used as a source of capture antigen in EIA and MAIA. Initially, the vaccine was 
concentrated with Amicon 10K filter centrifugal concentrator tubes (Merck 
Millipore) using PBS and according to the manufacturer guidelines. 
4.1.4 HAdV type C05 hexon protein (II) 
In Study II, hAdV type C05 hexon protein was used as a capture antigen in MAIA. 
The hAdV type C05 hexon protein was obtained from a previous research project 
at the Department of Virology, University of Turku. Originally, the hAdV C05 
prototype was kindly provided by the Centres for Disease Control and Prevention 
(Atlanta, GA, USA). The virus was propagated in Hela cell culture and hexon 
protein was purified by anion-exchange chromatography as previously described 
(Waris and Halonen, 1987). 
4.1.5 Controls and detection antibodies (I-III) 
In Studies (II-III) purified human IgG (hIgG) (Sigma-Aldrich, St.Louis, MO) and 
rabbit anti-hIgG (Thermo Scientific, Rockford, IL, USA) were used as positive 
controls in MAIA. Human serum albumin (HSA), (Sigma-Aldrich, St.Louis, MO) 
was used as a negative control in MAIA. In Study III, additionally purified human 
IgM (hIgM) (Jackson ImmunoResearch Laboratories Inc.) was used as a positive 
control.  
Polyclonal rabbit anti-human IgG/HRP (Dako, Denmark; Studies I-III) and 
polyclonal rabbit anti-human IgM/HRP (Dako, Denmark; Study III) were used for 
the determination of human IgG and IgM, respectively in EIAs. 
The anti-hIgG coated green-emitting UCNPs (upconverting nanophosphors; 
Er-UCNP-anti-hIgG; Studies II-III) and the anti-hIgM coated blue-emitting UCNPs 
(Tm-UCNP-anti-hIgM; Study III) was used for the detection of human IgG and 
IgM, respectively in MAIAs. The green-emitting NaYF4:Yb3+,Er3+ (Er-doped 
UCNP; 30–40 nm) and blue-emitting NaYF4:Yb3+,Tm3+ (Tm-doped UCNP; 35–40 
nm) UCNPs were synthesized as described earlier (Kale et al., 2013, 2016; 
Ylihärsilä et al., 2013). 
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Polyclonal rabbit anti-human IgG (Dako, Denmark) and polyclonal rabbit anti-
human IgM (Dako, Denmark) were conjugated onto the surface of Er-UCNPs and 
Tm-UCNPs, respectively as has been described before (Kale et al., 2016).  
4.2 Assay methods 
4.2.1 Enzyme immunoassay (I-III) 
In-house enzyme immunoassay was used for the detection of anti-RSV IgG 
antibodies (in Studies I-II) and anti-H1N1pdm09 vaccine antigen IgM and IgG 
antibodies (in Studies II-III). The enzyme immunoassay principle is shown in 
Figure 6.  
In Study I, anti-RSV IgG antibodies were analysed in 867 child serum samples 
diluted 1/300 (samples collected at 13, 24 and 36 months from 289 individuals) by 
EIA. In Study II, anti-H1N1pdm09 vaccine antigen IgG antibodies were analysed 
in 576 child serum samples diluted 1/300 (samples collected at 13 and 24 months 
from 288 individuals) by EIA. In Study III, anti-H1N1pdm09 vaccine antigen IgM 
and IgG antibodies were analysed in 180 Pandemrix-vaccinated adult serum 
samples (samples collected at day 0 and 28 and 180 days after vaccination from 60 
individuals) by EIA. The samples were tested at 1/100, 1/300, 1/1000, 1/3000 and 
1/10000 dilutions for IgM detection, and at 1/1000, 1/3000, 1/10000, 1/30000 and 
1/100000 dilutions for IgG detection.  
 
Figure 6.  RSV-specific antibodies in the specimen react with solid-phase bound RSV antigen. 
IgG antibodies bound to the antigen are detected with anti-human IgG labelled with 
peroxidase catalysing colour formation in a substrate reaction. The intensity of the 
colour is measured spectrophotometrically at 450 nm. 
wash
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Secondary antibody
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The virus antigen was dissolved in phosphate-buffered saline (PBS), pH 7.2 (2,5 
μg/ml for RSV or 1,25 μg/ml for H1N1pdm09 vaccine antigen, 100 μl/well) and 
adsorbed onto the wells of polystyrene microtiter plates (Combiplate, 96-well 
format, Thermo Scientific, USA) at room temperature for 24 h and then stored at 
+4°C before use. Assay optimisation and stability tests showed that the antigen 
coated plates (the antigen is under PBS and plates are sealed) can be stored up to 6 
months at +4°C without the loss of assay sensitivity and assay quality. Before 
using the plates were washed once with 400 ul/ well of washing buffer (PBS 
containing 0.5% Tween 20). Briefly, 100 μl of the 1/300 diluted serum sample in 
assay buffer containing 5% normal swine serum and 0.5% tween 20 in PBS was 
added in duplicate to the plate well and incubated for 2 h at 37°C. After the 
incubation, the plate was emptied and washed row by row for three times. 100 
μl/well of either polyclonal rabbit anti-human IgG/HRP (diluted 1/2000 in assay 
buffer) or polyclonal rabbit anti-human IgM/HRP (diluted 1/1000 in assay buffer) 
were added to the plate wells depending on the detection of bound serum IgG or 
IgM antibodies. The plate was incubated for 1 h at 37°C. After the incubation, 
unbound antibodies were washed out by three times with 400 μl/well of washing 
buffer. After washing, 100 μl/well of fresh substrate solution (0.3% 1,2-
phenylenediamine and 0.02% hydrogen peroxide in citrate-phosphate buffer, pH 
5.5) was added and plates were incubated in dark at room temperature during 15 
min. The reaction was terminated by adding 100 μl/well of 1 M hydrochloric acid. 
The absorbance was measured by a multilabel plate reader (VICTOR 3 V – 1420 
Multilabel Counter, Perkin Elmer) at 490 nm. 
Since there is some inter-assay variation in original absorbance values 
obtained in individual antibody determinations we standardised the assay by 
converting the raw absorbance data to EIA units. Each EIA plate included control 
sera which were prepared as a pool of earlier tested patient sera. Negative control 
serum is a pool of sera with a result of <1 EIA units. Positive control serum is a 
pool of high positive serum specimens (100 EIA units). Accuracy control serum 
is a patient serum with intermediate EIU value (60-70 EIA units). All specimens 
were tested in duplicates. The raw absorbance values (A450) of samples were 
converted to EIA units using the Negative Control (denoted as 0 EIA units) and 
Positive Control (denoted as 100 EIA units) as standards to make the calibration 
linear plot and to calculate the unit values of individual samples. The positivity 
cut-off level was calculated as the mean of Negative Control + 3 standard 
deviations (SD).  
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4.2.2 RSV detection and typing by PCR (I-II) 
Nasal swabs collected from the children with respiratory infection symptoms or during 
scheduled control clinic visits were suspended in phosphate buffered saline and 
subjected to automated virus nucleic acid extraction by utilising NucliSense easyMag 
(BioMerieux, Boxtel, Netherlands) or MagnaPure 96 (Roche, Penzberg, Germany) 
instrument. Virus RNA extraction was followed by reverse transcription and cDNA 
amplification using real-time qPCR assay designed for RSV, rhinoviruses, and 
enteroviruses as previously described (Toivonen et al., 2015; Kutsaya et al., 2016).  
In Study I, those samples that were RSV positive as detected by initial PCR 
test were subjected to repeated RNA extraction and RSV-N A/B group typing 
PCR. Random hexamer primers from the QuantiTect Reverse Transcription kit 
(Qiagen, The Netherlands) and 5 μl of extracted RNA were used to perform 
reverse-transcription reactions. The amplification protocol, primers, and probes 
were described in detail earlier (Hu et al., 2003; Kutsaya et al., 2016). 
4.2.3 Multiplex microarray immunoassay (II-III) 
Multiplex microarray immunoassay principle and array layout (Study II) are shown 
in Figure 7. 
A                                                                       B 
 
Figure 7. (A) Multiplex microarray immunoassay principle (II). Biotinylated virus antigens and 
control proteins are printed in array-in-well 4x5 format on streptavidin-coated plates. 
Human serum IgG antibodies binding to the corresponding antigens and positive 
controls are detected by secondary anti-hIgG coated UCNPs. Upon 980 excitation by 
laser diode, green upconversion luminescence is emitted and spots signal intensities 
are measured by photoluminescence imager. Antibody responses to different antigens 
are differentiated based on the spot position in the array. (B) Microarray layout with 
printed in duplicates antigens (H1N1pdm09 vaccine ag, IAV H1N1, IAV H3N2, IBV 
Victoria, IBV Yamagata, RSV, hAdV type C05 hexon protein), positive controls (hIgG, 
anti-hIgG) and negative control (HSA) spots.  
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In both Studies II and III, virus antigens, as well as control proteins, were 
biotinylated with biotin isothiocyanate (BITC) as described in detail in Study II. 
The biotinylated virus antigens and control proteins were printed on the bottom of 
the 96-well streptavidin-coated KaiSA microplates (Kaivogen Co., Turku, Finland) 
using a non-contact Nano-Plotter 2.1 array printing instrument (Gesim, Germany).  
In Study II, a multiplex microarray immunoassay for the detection of IgG 
antibodies against seven virus antigens (H1N1pdm09 vaccine ag, IAV H1N1, IAV 
H3N2, IBV Victoria, IBV Yamagata, RSV, hAdV type C05 hexon protein) was 
developed. The biotinylated virus antigens (n=7) and controls (hIgG, anti-hIgG, 
HSA, n=3) were printed in duplicates forming 4x5 array-in-well consisting of 20 
spots. With the MAIA, 1482 child serum samples were screened. MAIA procedure 
was described in detail previously (Kazakova et al., 2019). Briefly, 50 μl of the 
1/100 diluted serum sample in assay buffer was added in duplicate to the pre-
washed microarray-containing well and incubated for 2 h at room temperature. 
After the incubation, the wells were washed three times. A 50 μl/well of anti-hIgG 
coated UCNPs (Er-UCNP-anti-hIgG) were added to the wells and incubated for 40 
min at room temperature with shaking. The wells were washed four times and dried 
for 2 h before the wells were imaged. For multianalyte detection, an anti-Stokes 
photoluminescence imager was constructed (Figure 9). For the descriptions of the 
instrument used see below. To evaluate the inter-assay variation and determination 
of antibody concentrations in MAIA units, negative and positive control samples 
were included in each plate. The MAIA results were compared to the reference 
RSV IgG and H1N1pdm09 vaccine ag IgG EIAs for 576 serum samples. 
In Study III, a multiplex microarray immunoassay was developed for the 
simultaneous detection of IgM and IgG antibodies against two virus antigens 
(H1N1pdm09 vaccine ag and IBV Yamagata). The assay principle and array layout 
are shown in Figure 8. Biotinylated virus antigens (n=2) and controls (hIgM, hIgG, 
anti-hIgG, HSA, n=4) were printed in duplicates forming a 3x4 array-in-well 
consisting of 12 spots. With the MAIA, 180 Pandemrix-vaccinated adult serum 
samples were screened. Five serum dilutions (1/100, 1/300, 1/1000, 1/3000 and 
1/10000) were added in duplicates in each assay run with the purpose to determine 
the antibody end-point titre to H1N1pdm09 vaccine ag. The assay was performed 
as described earlier for MAIA in Study II with the exception that IgM antibodies 
were detected in addition to IgG antibodies. A 50 μl/well of each type of detection 
antibodies (Er-UCNP-anti-hIgG and Tm-UCNP-anti-hIgM) were added 
simultaneously. The plates were incubated for 40 min at room temperature with 
shaking. After washing and drying two images of each well were produced with 
anti-Stokes photoluminescence imager at the green 550 nm and blue 470 nm 
channels. Negative and positive control calibrator sera were included in each plate 
and used to convert microarray specific signal counts into MAIA IgM and IgG 
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units. The MAIA results were compared to the reference H1N1pdm09 vaccine ag 
IgM and H1N1pdm09 vaccine ag IgG EIAs run for the same samples. The cut-off 
levels and the determination of antibody endpoint titers were described in detail in 
Study III.  
 
Figure 8.  Dual mode (IgG and IgM) multiplex microarray immunoassay principle and array 
layout. The microarray consists of 12 spots including antigens  (H1N1pdm09 vaccine 
ag and IBV Yamagata), positive controls (hIgM, hIgG, anti-hIgG) and negative control 
(HSA). Human serum IgM and IgG antibodies binding to the corresponding antigens 
and positive controls are detected simultaneously by secondary anti-hIgM and anti-
hIgG coated UCNPs in the same well. Upon 980 excitation by laser diode, blue and 
green upconversion luminescence is emitted and spot signal intensities are measured 
by photoluminescence imager. Antibody responses to different antigens are 
differentiated spatially based on the spot position. Antibody classes are differentiated 
spectrally based on blue or green colour of the signal.  
The microarray immunoassays (II-III) were measured with the microtiter plate 
reader (Hidex Oy, Turku, Finland) modified for the anti-Stokes photoluminescence 
imaging (Figure 9). The detection is based on the ability of UCNPs to convert low-
energy infrared radiation to high-energy visible light. The plate wells were excited 
with an infrared laser at the wavelength of 976 ± 2 nm with 7 W optical power. The 
laser beam passes through a long-pass filter and is reflected to the well from a hot 
mirror. UCNPs emit anti-Stokes photoluminescence which is collected with 50 mm 
camera lens. Two short-pass filters block scatter laser radiation. The upconversion 
photoluminescence is imaged using short-pass filters (Chroma Technology, 
Rockingham, VT, USA). The green-emitting Er-UCNP-anti-hIgG and blue-
emitting Tm-UCNP-anti-hIgM are imaged through a 550 nm and 470 nm channels, 
respectively. The images are produced with a cooled CCD camera with a 50 mm 
objective lens using the following parameters: 2x binning, 2.2 s exposure time per 
well. The instrument is described in more detail in a previous publication 
(Ylihärsilä et al., 2011). 
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Figure 9.  Anti-Stokes photoluminescence imager construction for multianalyte detection in MAIA 
(II-III) (Modified from Ylihärsilä et. al., 2011). 
 
Figure 10. Fluorescent colour collection of MAIA 96-well plate. 
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UCNPs signal counts were obtained from the microarray well image and spot 
detection by calculating the mean intensity of the pixels within the spot using 
ImageJ software version 1.43n (Figure 10). The images were saved in 16-bit sif-
file format. Since each analyte spot was printed in duplicates and each serum 
sample was tested in two replicate wells, average signal counts for each analyte 
were calculated as a mean signal from 2 replicate spots in 2 replicate wells. The 
specific signal of each analyte spot was calculated in Excel by subtracting HSA 
spot signal (assay background) from the average signal of the analyte spot. 
4.2.4 Hemagglutination inhibition assay (III) 
In Study III, serum samples obtained from Pandemrix-vaccinated adults were 
analysed by HI to determine antibody endpoint titers and vaccination efficacy. The 
HI test essentially was performed according to WHO guidelines (World Health 
Organization. and WHO Global Influenza Surveillance Network., 2011). 
H1N1pdm09 (A/California/07/2009 strain) vaccine virus was used in the HI test. 
The test was conducted on U-based 96-well microtiter plates using 0.5%/vol turkey 
erythrocytes. The serum samples were serially diluted from 1/10 to 1/1280. The 
serum samples with HI titers <10 were assigned a titer value of 5.  
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 Results and discussion 
5.1 Serological follow-up of respiratory infections in 
early childhood 
In publications I and II, serological studies were conducted on respiratory virus 
infections and reinfections in young children. Figure 11 provides a general 
description of the number of samples, assay methods and study design. In publication 
I, RSV disease burden in early childhood was analysed. The analysis was based on 
identifying viral pathogens by RT-PCR from nasal swabs taken during acute infection 
episodes and detecting anti-RSV IgG antibodies by EIA in child serum specimens 
taken annually at scheduled visits at the study clinics. We estimated primary RSV 
infection and reinfection rates in children 0-3 years old. RSV-positive acute 
respiratory infections (ARIs) were analysed to compare proportions of primary 
infections and reinfections with RSV group A and B strains. In publication II, we 
described the development of the multiplex microarray immunoassay for the 
simultaneous detection of IgG antibodies against RSV, adenovirus and influenza 
viruses. With the established assay we conducted a large serological study in the 
young children and compared the microarray assay results to reference EIA methods.  
5.1.1 RSV enzyme immunoassay optimisation (I-II) 
Anti-RSV IgG antibodies were analysed by an in-house EIA in serum samples 
collected at 1 year, 2 years and 3 years from 291 children. Anti-RSV IgG antibody 
levels were determined from altogether 873 serum specimens and the seropositivity 
status of serum samples was determined to estimate RSV disease burden in early 
childhood. To obtain low background levels of nonspecific binding (OD < 0.200) 
for seronegative samples and buffer controls, and high binding of RSV-specific 
IgG antibodies, and to prevent nonspecific adsorption of the anti-IgG conjugate, 
optimal EIA parameters were invesigated. During the development of the assay 
following parameters were evaluated: i) antigen concentrations, ii) different serum 
dilutions, iii) conjugate concentrations. 
The plates were coated and tested with the following RSV antigen 
concentrations: 5µg/ml, 2,5µg/ml, 1,25µg/ml and 0,625µg/ml. The optimal RSV 
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concentration of 2,5µg/ml (0,25 ug/well in 100 ul) was chosen for the following 
analysis. Anti-human IgG-peroxidase conjugate has been tested at 1:1000, 1:2000 
and 1:3500 dilutions. The conjugate dilution of 1:2000 was chosen. 
 
Figure 11. The workflow of respiratory infections follow-up in the birth-cohort of children 0-3 years 
of age (Studies I-II). 
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Serum specimens of young children contain much lower levels of 
immunoglobulins than adults and the IgG concentrations gradually increase with 
increasing age reaching adult values at 5-10 years of age (Johansson SG and Berg, 
1967). Since serum IgG levels were considerably lower in the studied very young 
children as compared to those in adults, we modified the original assay and 
analysed child sera in lower serum dilutions of 1/300 (I-II) in contrast to 1/1000 
dilution designed for adults (III). In this manner, the absorbance values in the 
analysis were at a higher level and the dynamic range of the RSV IgG EIA assay 
became wider and more suitable for analyzing anti-RSV IgG levels in young 
children (Figure 12).  
 
Figure 12. RSV IgG antibody analysis of random STEPS study samples in different serum 
dilutions by EIA. Serum dilutions of 1:300 and 1:1000 have been used. Antigen 
coating concentration 2,5 ug/ml (0,25 ug/well in 100 ul) and anti-human IgG-
peroxidase conjugate dilution of 1:2000 has been used. 
Table 2 describes the interassay variation in 25 individual anti-RSV IgG EIA 
determinations and Figure 13 describes the variation of an intermediate (60-70 
EIA units) control sample between the assays. The percentage of the coefficient of 
variation (CV%) of absorbance values was 30% for high positive control 
specimens and 16% for negative control specimen. The mean EIA IgG unit values 
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for the intermediate positive sample were 64, SD was 9 and CV% 13. Thus the 
conversion of original absorbance values to EIA IgG unit values reduces the 
variation significantly and makes the comparison of the data from one assay to 
another more reliable. 
Table 2. Inter-assay variation characteristics of anti-RSV IgG determinations. 
Plate no. Pos ctrl 
Absorbance 
Neg ctrl 
Absorbance 
Cut-off 
Absorbance 
Intermediate ctrl 
IgG units 
1 0.748 0.048 0.099 55 
2 0.765 0.063 0.133 75 
3 0.822 0.065 0.121 71 
4 0.673 0.085 0.149 65 
5 0.445 0.072 0.118 50 
6 0.833 0.065 0.136 64 
7 0.538 0.074 0.125 75 
8 0.544 0.084 0.133 77 
9 0.550 0.099 0.146 74 
10 0.818 0.074 0.111 72 
11 0.915 0.084 0.144 52 
12 0.748 0.075 0.129 62 
13 0.789 0.075 0.113 70 
14 0.837 0.075 0.141 57 
15 1.052 0.077 0.137 76 
16 1.216 0.073 0.129 74 
17 1.168 0.068 0.111 66 
18 0.901 0.074 0.130 72 
19 1.019 0.085 0.140 46 
20 1.328 0.094 0.155 78 
21 1.444 0.105 0.168 67 
22 0.975 0.069 0.174 66 
23 1.037 0.077 0.134 69 
24 1.189 0.079 0.138 68 
25 1.312 0.094 0.170 63 
Mean 0.882 0.075 0.131 64 
SD 0.261 0.012 0.018 9 
CV % 30 16 14 13 
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Figure 13. Interassay variation of anti-RSV IgG determination. Intermediate control of pooled 
serum samples included in each test. The mean ± SD was 64 ± 9 with a CV of 13%. 
Black dots indicate values outside the acceptance criteria of expected value ± 20%. 
Since respiratory infections in children are common and many infection episodes 
remain subclinical or mild, clinically recognized infections do not allow a reliable 
estimation of the disease burden of any respiratory infection including RSV 
infection. Thus analysing the anti-RSV-IgG serostatus of young children provides a 
better estimate of RSV disease burden than the identification of clinical infections 
with PCR detection of RSV nucleic acids. However, since in young children the 
immune system is not fully developed, some children may show weak or 
undetectable induction of anti-RSV antibodies during RSV infection. The 
individual variation in the humoral immune response is generally known to be 
wide. In our study material it was possible to compare the RSV PCR-positivity and 
serum anti-RSV IgG levels (at 13 and 24 months) in 186 children of whom nasal 
swab specimens had been collected during the first 2 years of life. Children with a 
previous positive RSV PCR test obtained at different times (at ages 1 to 12 months 
of age) before the collection of the 13 months serum specimens showed clearly 
higher EIA IgG unit values as compared to those collected from RSV PCR 
negative children (Figure 14). However, many PCR negative children were RSV 
seropositive. All individual test series included the seronegative control sample (0 
unit value) and three seronegative child sera. The cut-off for RSV seropositivity 
was determined as the mean absorbance value of negative control sera and 3 
seronegative child sera + 3 SD units. In most assays the sample was considered 
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seropositive if the RSV IgG EIA unit values were higher than 5. In different assays 
the seropositivity cut-off value corresponded to EIA unit values between 4 and 7, 
depending on negative controls values and SD.  
 
Figure 14. Distribution of serum anti-RSV IgG EIA values in 13 months old children with or 
without a history of PCR confirmed RSV infection (N=186). PCR analyses were done 
at different times (1-12 months) before the collection of serum samples. For IgG units, 
the X-axis is set at an arbitrary cut-off level of 5 units. 
There were very few samples from PCR positive children that showed values lower 
than 5 EIA IgG units and they were very young children of less than 9 months of 
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age. The overall analysis of serum specimens indicated that serum specimens 
collected from those children whose nasal swab samples had been RSV nucleic 
acid positive at some point before sample collection showed EIA unit values higher 
than 5. Further statistical analyses strongly support the concept that a previous 
RSV infection detected by RT-PCR strongly correlates with seropositivity (Figure 
15). 
 
Figure 15. Normal distribution analysis of serum anti-RSV IgG EIA values in 13 months old 
children with or without a history of PCR confirmed RSV infection (N=186). 
ROC curve analysis and statistical compilation of the EIA unit values also show 
that with a seropositivity cut-off of 5 EIA units the sensitivity and specificity of the 
assay are excellent (Figures 16 and 17). The data strongly indicates that EIA 
values higher than 5 are seropositive with very high certainty, values from 1 to 5 
are border line positive/negative and values less that1 unit are considered 
seronegative.  
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Figure 16. ROC curve of serum anti-RSV IgG EIA values in 13 months old children with or 
without a history of PCR confirmed RSV infection (N=186). 
The sensitivity indicates the rate of anti-RSV IgG detection in a child with a history 
of PCR confirmed RSV infection. False positive indicates the detection of anti-
RSV IgG in a child without a history of PCR confirmed RSV infection. Data points 
were calculated for all possible cut-off IgG values with 1 unit interval (descending 
from left to right). The black dot indicates the cut-off value of 5 units. 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Se
ns
iti
vi
ty
 ra
te
False positive rate
AUC=86.6
Results and discussion 
 63 
 
Figure 17. Effect of cut-off on the anti-RSV IgG assay performance in 13-month old children 
(n=186). Sensitivity and specificity were calculated against an earlier RSV-PCR result. 
The black dot indicates the cut-off value of 5 units. 
5.1.2 RSV primary infection and reinfection rates (I-II)  
Study I revealed that RSV infections are very common in early childhood and 
many children suffer from repeated RSV infections during their first years of life. 
We analysed anti-RSV IgG levels in the children at 1, 2 and 3 years of age and 
estimated seropositivity rates, reinfection rates, mean RSV IgG levels after primary 
and repeated infections and the rate of RSV IgG antibody decline.  
Based on the positive anti-RSV IgG EIA result we determined RSV 
seroprevalence in the studied population. Figure 18 shows anti-RSV IgG 
seropositivity and reinfection rates in serially collected serum samples from 291 
children. We found that 37% of children (n=109) were RSV IgG seropositive by 
the age of 1 year. RSV seropositivity increased to 68% (n=198) at the age 2 years 
and to 86% (n=250) at the age 3 years. Out of 291 children, only 35 individuals 
(12%) remained RSV seronegative during the 3 years of follow-up. The 
discrepancy between the overall number of children and finally 
seropositive/seronegative children comprised 6 individuals who were initially 
seropositive but turned seronegative by 3 years of age.  
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Figure 18. RSV IgG seropositivity and reinfection rates by the age of children (n=291).  
Our findings indicate a relatively high RSV disease burden during the first year of 
life. Moreover, a high proportion of children were reinfected. A case of reinfection 
was defined when a rise in IgG levels of >25 EIA units was observed between the 
serial samples. Of children who were seropositive by the age of 1 year (n=109), 40 
individuals were likely reinfected (13% out of 291). The estimated RSV reinfection 
rate in seropositive children between 0-2 years was 19% (out of 291) by the age of 
3 years. 
Out of 109 children seropositive at the age of 1 year, 65 children (60%) were 
finally reinfected by the age of 3 years. One individual among them acquired two 
RSV reinfections. Out of 95 children who acquired primary RSV infection between 
1 and 2 years of age, 30 (32%) children became reinfected by the age of 3 years.  
Our serological findings on the high RSV primary infection and reinfection 
rates are supported by a clinical study conducted in the same study group (Studies 
I-II) and are consistent with previous studies (W. Paul Glezen et al., 1986; Hall et 
al., 1991; Law, Carbonell-Estrany and Simoes, 2002). 
Among this cohort (n=291), 186 children were monitored for acute respiratory 
infections (ARI) and provided a nasal swab sample during the infection episode. A 
symptomatic RSV infection was detected at least once in 66 (35%) of the 186 
children during the 0-2 years follow-up. Of the 66 RSV RT-PCR positive 
individuals, 92% developed anti-RSV IgG antibodies. Only five (8%) very young 
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children did not demonstrate anti-RSV IgG response. An RSV-positive ARI was 
documented twice in 10 children and three times in one individual. A rise in RSV 
IgG antibodies of >10 EIA units was revealed in those individuals. Our serological 
findings indicate that there was a high rate of mild or asymptomatic RSV 
infections.  
Out of 923 children followed more intensively for respiratory tract infection, 
data on acute respiratory tract infections were received from 824 children. Most of 
ARIs were caused by rhinovirus (63.5%). However, our study revealed RSV to be 
the most common viral cause of medically attended visits for ARIs in young 
children. 
At least one symptomatic RSV infection was detected in 254 (31%) of 824 
children at the age of 0-24 months (Toivonen et al., 2019). Among 254 children, 
223 had only one infection, 27 children had one reinfection and 4 children had two 
reinfections. Toivonen and colleagues reported an estimated rate of 37 RSV 
infections per 100 children per year. The reported RSV infection rate was higher 
than in other studies among children aged <3 years (Nokes et al., 2008; Simpson et 
al., 2016; Heikkinen et al., 2017). However, our serological findings support this 
data and show a high rate of subclinical RSV infection within the first 3 years of 
life. 
The clinical study conducted by our colleagues shows that RSV infections are 
associated with substantial morbidity. Even though the RSV-associated 
hospitalization is very low (1-2%) as documented in many studies (Forster et al., 
2004; Iwane et al., 2004; Simpson et al., 2016; Scheltema et al., 2017; Toivonen, 
2019), the majority of RSV infections require treatment at home or at outpatient 
clinics. The study of our colleagues (Toivonen et al., 2019) demonstrated that RSV 
infections in this child cohort were more severe than other ARIs, with an acute 
otitis media being diagnosed more often (44%) and a high rate of prescribed 
antibiotics. Of 824 children 188 (23%) had physician visits due to RSV infection 
and 7 (0.8%) very young children (<11 months of age) had RSV-associated 
hospitalizations. The frequency of RSV infections increased with age from 10-16% 
before 5 months of age, to 32% at the age of 6-11 months, and to 42% at the age of 
12-24 months (Toivonen et al., 2019). 
RSV-positive ARI samples were identified as either group A or group B by 
RSV-N A/B group typing by PCR (Study I and unpublished data). We have typed 
samples from 248 RSV positive individuals (In 6 cases the determination failed due 
to a low amount of viral RNA in the samples). The results are presented in Figure 
19.  
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Figure 19. An RSV-positive ARI samples typing in 248 children.   
Among 248 children with primary RSV infection, 131 and 117 children were 
infected with RSV group A and RSV group B, respectively at the age of 0-24 
months. Out of 248 children, reinfection was documented in 29 children (12%). 
There were a few cases with three infections but some samples were missing or the 
sample quality was inadequate for virus RNA determination. Of 131 children with 
RSV group A infection being their primary infection, seven had a group B and 
seven had a group A infection during the reinfection episode. Of 117 children with 
a group B infection as their primary infection, six had a group B and nine had a 
group A reinfection. Our data suggest that both strains are equally pathogenic and 
reinfections occur with either homologous or heterologous strains. However, there 
have been suggestions that RSV A viruses are more prevalent and slightly more 
pathogenic compare to RSV B viruses (Melero and Moore, 2013). Moreover, RSV 
neutralizing antibodies were reported to be highly group-specific, so the 
incorporation of strains or antigens of both RSV groups (A and B) in future RSV 
vaccine may be optimal (Charles J. Sande et al., 2013). 
5.1.3 The development and validation of multiplex 
microarray immunoassay (II) 
In study II, a multiplex antigen-based microarray-in-well immunoassay (MAIA) 
was developed for seven virus antigens. The assay was developed for simultaneous 
detection of IgG antibodies against partially purified IAV H1N1, IAV H3N2, 
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influenza B virus (IBV) Victoria, IBV Yamagata, and RSV whole viruses, purified 
AdV-C5 hexon protein, and IAV H1N1pdm09 vaccine antigen.  
Initially, the produced viruses and available antigens were tested in EIA with 
no-sample, two negative, two low positive, two medium positive and two high 
positive child serum samples. Chess board titration method was applied to 
determine the optimal antigen, conjugate and serum sample dilutions. Then the 
antigens were biotinylated and tested in EIA on streptavidin-coated plates with a 
series of serum samples. Thereafter multiplex immunoassay was developed with 
the biotinylated antigens. First, biotinylated antigens were tested in a singleplex 
whole well assay format where one antigen was plated to cover the whole well 
surface. Then, the microarray 5x4 format was designed including 7 antigens and 
controls. The microarray immunoassay results were compared to the reference EIA 
assays at all stages. 
During the multiplex microarray immunoassay development different 
manufacturer’s streptavidin-coated 96-well plates were tested for their suitability in 
MAIA tests. White flat bottom 96-well streptavidin-coated KaiSA microplates 
(Kaivogen Co.,Turku, Finland) were used in further experiments for which the best 
signal to background ratio and better spot morphology were observed. To optimise 
the printing conditions different printing buffer compositions, concentrations of 
virus antigens and blocking buffers were used (data not shown). The visual 
examination of array spots were performed during microarray images analysis. The 
spot signal was excluded from the mean antigen signal in case of one inadequate 
spot out of four spot replicates (two duplicate antigen spots in two duplicate wells). 
If more than one antigen spot was printed with inadequate morphology a sample 
test was repeated.  
In the preliminary experiments, weaker spot signals and suboptimal spot 
morphology were obtained with new partially purified whole virus antigens in 
contrast to previously used AdV-C5 hexon protein. The reason for that appeared to 
be excessive biotinylation and free unbound biotin in the antigen stock solution. 
Therefore, either the antigens with insufficient performance were further purified 
with Amicon Ultra 10K centrifugal filter device (Merck Millipore) or newly 
biotinylated antigens were produced. Also, different incubation times, at different 
temperatures (RT or at +37°C), with or without shaking were tested to achieve 
higher signal intensities in the assay. We extended the incubation time with serum 
samples at RT until 2 hours in contrast to the previous assay protocol.  
Despite all modifications and improvements to obtain higher signal intensity, 
the bottleneck was in the high assay background. Since the multiplex immunoassay 
was developed to detect IgG antibodies in very young children <3 years of age, it 
required to be highly sensitive to detect low levels of immunoglobulins and 
discriminate negative samples from samples with low positivity. For high 
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specificity and for low background in MAIA test different concentrations and 
compositions of the assay buffer were evaluated. The addition of 1% FCS to the 
Kaivogen assay buffer gave the highest ratio between the IgG positive signal and 
IgG negative signal values. The hypothesis was that very young children have anti-
bovine antibodies due to high milk consumption. Bovine serum albumin was used 
for plate blocking and apparently child serum IgG antibodies tend to bind to the 
plate and cause non-specific background.  
The performance of the developed MAIA has been demonstrated in Figure 20. 
The array well without serum samples shows reagent background. Only assay 
buffer containing secondary antibodies was added to that well. Fluorescent signals 
come only from hIgG control spots which were positive control spots for binding 
of secondary antibodies labelled with UCNPs. With a negative serum sample signal 
from hIgG control spots obtained along with anti-hIgG control spots. When the 
positive control serum sample was included, all antigens and control spots except 
HSA emitted green light due to the detection of bound serum IgG antibodies. A test 
serum sample with anti-RSV and anti-hAdV5 hexon IgG antibodies gave a signal 
from the corresponding antigen spots. Fluorescent colours were related to signal 
intensity: green colour corresponded to 7000-35000 signal counts, yellow to 
35000-45000 and red colour to 45000-65000 signal counts. The signal measured 
from the HSA spot indicates the assay background and it corresponded to 
approximately 5000 signal counts. Antigen specific signals were calculated by 
subtracting the HSA signal from the average signal of viral antigen spots. The 
specific signal was converted to MAIA units by linear correlation with negative 
and positive controls.  
With the established method, we tested 768 serum samples from 1-year-olds 
and 714 serum samples from 2-year-olds (Study II). To validate the MAIA method 
we compared the results to reference EIA where IgG antibodies to RSV and 
H1N1pdm09 vaccine ag were determined in 576 samples from 1 and 2 years old 
children (n=288). We conducted a receiver operating characteristic (ROC) curve 
analysis to estimate MAIA performance and to determine the cut-off values for 
antibody positivity (Figure 21). The sensitivity and specificity of the assay were 
calculated against an earlier EIA result. The intersection of the sensitivity and 
specificity lines indicated the optimal ratio and cut-off value of 12 and 8 units for 
RSV and IAV H1N1 vaccine ag, respectively. The cut-offs for other antigens were 
calculated as the means of negative controls plus 6 SD.  
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Figure 20. Fluorescent array-in-well images, their 3D models and signal intensity counts.  
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Figure 21. ROC curves and the effect of cut-off on anti-RSV IgG and anti-IAV H1N1 vaccine ag 
MAIA performance in 1-2 year old children (n=576).  
At age 1 year, 37% (n=106) and 38% (n=109) children had anti-RSV IgG 
antibodies as detected by EIA and MAIA, respectively. By the age of 2 years, 
seropositivity rates increased to 68% (n=196) and 69% (n=199) as detected by EIA 
and MAIA, respectively. Anti-H1N1pdm09 vaccine ag IgG seropositivity rates 
detected by EIA and MAIA were also at similar levels: 58% (n=167) and 57% 
(n=164) in 1-year-olds, and 83% (n=240) and 72% (n=290) in 2-year-olds, 
respectively. A high degree of correlation was observed between EIA and MAIA 
results which confirm that MAIA is well suitability for serological studies. MAIA 
has advantages compared to EIA based on its ability to detect antibodies against 
several antigens simultaneously in one well. MAIA saves the antigens, serum 
sample volumes and the labour time. Gageldonk has estimated that the multiplex 
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immunoassay is cost-effective compared to enzyme immunoassay when more than 
three different antigens are measured in one assay (Gageldonk et al., 2008). 
5.1.4 Serological follow-up by multiplex microarray 
immunoassay in young children (II) 
In publication II, we have estimated the seropositivity rates by MAIA against 
seven virus antigens in serum samples collected from 1 (n=768) and 2-year-old 
(n=714) children (Figure 22).  
 
Figure 22. Seropositivity percentage for RSV, AdV-C5 hexon protein, IAV H1N1pdm09 vaccine 
antigen, IAV H1N1, IAV H3N2, IBV Victoria and IBV Yamagata in 1 year (lighter 
colour) (n=768) and 2 year (darker colour) (n=714) serum samples by MAIA. 
Seropositivity rates against all antigens increased 1.3-2.07 fold by 2 years of age. 
Interestingly, very good agreement was found when comparing the results from 
RSV seropositivity rates detected by MAIA in a larger children group (>700 
individuals) against the previously detected seropositivity rates by EIA in a cohort 
of 291 individuals (Study I). Based on the serology data, RSV infection was 
observed at least in 38% of children during their first year of life and in 68% by the 
age of 2 years. The findings validate that MAIA with multiple analytes detection 
agrees extremely well with a single analyte detecting EIA.  
The seroprevalence against other respiratory virus antigens and IAV H1N1 
vaccine ag were also relatively high during the first year of life and increased 
against all antigens by the age of 2 years. We thoroughly analysed antibody levels 
during 1 and 2 year against each antigen and estimated possible reinfection rates. 
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Mean antibody levels against IAV H1N1pdm09 vaccine ag, IAV H1N1, IAV 
H3N2, and IBV Yamagata stayed at a rather similar level between 1 and 2 year 
samples indicating that there were likely no reinfections. In addition, a low rate of 
influenza infections was detected by PCR, when our colleagues analysed nasal 
swabs taken at the onset of acute respiratory infections in this study group (Teros-
Jaakkola et al., 2017). Even though the study children were potentially exposed to 
influenza viruses during 3 epidemic seasons, the incidence of influenza infection 
was 2.7-5.1% and influenza cases were mostly non-severe in 0-2 years old 
children. Nevertheless, that can be explained by the high influenza vaccination 
coverage in the study population. In their study, Teros-Jaakkola and co-workers 
(2019) found that 22–47% of 6-23 month-old children were vaccinated with a 
seasonal influenza vaccine and 80% with IAV H1N1pdm09 vaccine (Pandemrix) 
in the epidemic season 2009–2010 (time line when 1 year samples were collected). 
High vaccination coverage was supported by the MAIA data since we observed 
54% and 71% seropositivity rates against IAV H1N1pdm09 vaccine ag at the age 
of 1 and 2 years. The vaccine effectiveness against pandemic influenza was 
claimed to be 97% in this study group (Teros-Jaakkola et al., 2019). The results 
from this serological study by MAIA (Study II) and the Teros-Jaakkola et al., 
(2019) data support the conclusion that the vaccine against the pandemic influenza 
was highly effective in young children. 
In contrast to influenza, RSV infections caused a high disease burden in the 
studied children. The incidence of medically attended RSV infection was 
consistently higher than that for influenza. The rate of RSV primary infections and 
reinfections remained high throughout the first 2 years of life and the infection 
frequently required healthcare visits. Among the MAIA tested samples, 450 paired 
1 and 2 year samples from the same individuals were selected and analysed for the 
possible reinfection rates. Of the selected children, 38% (n=170) acquired the 
primary RSV infection during the first year of life and 40% were likely reinfected 
(n=68) by the age of 2 years. In the course of this work, we discovered that 
children who developed ~ 60% higher antibody level after primary infection were 
likely protected from reinfections. Very young children (< 1 year) developed lower 
antibody levels against respiratory viruses. We found that when reinfection occurs, 
children develop significantly higher antibody levels. High RSV disease burden in 
young children emphasizes the need for RSV vaccines and antiviral drugs.  
Results and discussion 
 73 
5.2 Simultaneous measurement of influenza A 
virus-specific IgM and IgG antibodies by 
multiplex microarray immunoassay in 
Pandemrix vaccinated adults (III) 
In Study III, we describe the development of a multiplex microarray immunoassay 
for the simultaneous detection of IgM and IgG antibodies in serum samples against 
two virus antigens (IAV H1N1pdm09 vaccine ag and IBV Yamagata). We 
investigated the feasibility of MAIA method in vaccine studies and analysed 
pandemic influenza A(H1N1pdm09) vaccine induced humoral immunity. Virus-
specific antibodies are commonly regarded as markers of partial or complete 
immunoprotection however, most studies concentrate on IgG antibody class when 
the immunogenicity of a vaccine is investigated.  We determined two classes of 
antibodies (IgM and IgG) in serum samples obtained from adult individuals before 
and after vaccination with a pandemic influenza A H1N1pmd09 vaccine. Healthy 
volunteers aged 18-65 years (n=60, median age 23 years) were investigated for 
antibodies against H1N1pdm09 vaccine antigen by HI, EIA, and MAIA. 
Altogether 180 serum samples from 60 individuals drawn before the vaccination 
(day -3 - 0) and on an average of four weeks (day 28) and 6 months (day 180) after 
the vaccination were analysed by each of three methods.  
MAIA was developed to measure viral antigen-specific IgM and IgG 
antibodies against several analytes simultaneously in one assay well. The detection 
was based on secondary anti-human IgM and IgG antibodies coated on the surface 
of two types of UCNPs (Tm-UCNP-anti-hIgM and Er-UCNP-anti-hIgG). The 
ability of UCNPs to emit photoluminescence at different wavelengths allows the 
simultaneous detection of different serum immunoglobulin classes. In a previous 
study (Kale et al., 2016), the spectral cross-talk and cross-reactivity between 
UCNPs were tested and they were found to very low of non-existing.  
We have adapted the assay method for measuring antibodies against IAV 
H1N1pdm09 vaccine antigen and partially purified IBV Yamagata. As we analysed 
influenza A vaccine-induced antibody responses, the influenza B virus was 
included in the microarray as an additional control to confirm that the rise of 
antibodies is solely vaccine antigen-specific. The presence of one UCNP-conjugate 
type in a single well did not interfere with the measurement of another UCNP-
conjugate type. Figure 23 shows that there was no cross-reactivity between the 
secondary antibodies and both IgM and IgG antibody classes can be reliably 
detected simultaneously.  
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Figure 23. Fluorescent microarray-in-well images and IgM and IgG specific signal counts of 
samples at day 0, day 28 and day 180 before and after the vaccination from the same 
individual.   
To validate the MAIA assay we performed EIA and determined anti-H1N1pdm09 
vaccine antigen IgM and IgG antibody levels and endpoint titers in 60 individuals. 
Serum samples were tested at 5 dilutions and endpoint titers were calculated with 4 
Day 0                  Day 28              Day 180
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Parameter Logistic (4PL) curve. EIA absorbance was converted to EIA IgM and 
IgG units and MAIA specific signal counts to MAIA IgM and IgG units. The unit 
values were calculated from the linear plot using negative and positive control 
calibrator samples in each assay run. The detailed description of the assays and 
seropositivity cut-off values has been provided in publication III. 
We observed practically no pre-existing IgM antibodies before the vaccination. 
There was a significant rise in IgM (8.9 to 12.2-fold) and IgG (2.9 to 4.2-fold) 
antibodies against H1N1pdm09 vaccine antigen in EIA and MAIA, respectively, in 
four weeks after the vaccination, confirming vaccine-induced immunity. A rise in 
the mean IgM and IgG antibodies against IBV Yamagata was not observed in post-
vaccination samples. Anti-IBV Yamagata IgM antibodies were at a low level and 
pre-existing IgG antibodies stayed at an equally high level of 123 MAIA units in 
all three samples before and after the vaccination with influenza A vaccine. EIA 
and MAIA showed a strong agreement in both IgM and IgG unit values and 
endpoint titers (Figures are published in Study III). 
In the HI assay, we tested 180 serum samples in serial dilutions and determined 
endpoint titers before and after vaccination. We found a statistically highly 
significant positive correlation between IgM endpoint titers determined by EIA or 
MAIA and HI titers (p<0.001). IgG endpoint titers determined by EIA or MAIA 
also correlated very well with the HI titers (p<0.001). Four weeks after the 
vaccination, a significant increase in geometric mean titers was observed in each of 
the three assays (Table I, Publication III). The study by Trombetta et. al (2018) 
has also shown a good positive correlation between EIA and “classical” assays for 
immunological response to influenza A and B strains (HI, SRH and VN) 
(Trombetta et al., 2018).  
The HI test is commonly used in influenza vaccine studies and it has proved to 
correlate well with clinical protection. It is generally considered, that HI titers of 
≥40 provide protection against severe influenza illness. Based on this knowledge, 
we calculated the corresponding theoretical protection titers in the EIA and MAIA, 
and seroprotection rates by all three methods. In publication III, we compared 
endpoint titers and seroprotection rates before and after vaccination with IAV 
H1N1pdm09 vaccine as measured by the HI test, EIA and MAIA. Before the 
vaccination, 8 individuals (13%) showed an antibody titre of at least 1:40 in the HI 
test. Four individuals (7%) demonstrated theoretical “protective” IgM antibody 
titre by EIA and MAIA. Before the vaccination protective IgG antibody titers were 
documented in 11 (18%) and 12 (20%) of the individuals by EIA and MAIA, 
respectively. It has been shown in different age groups that some individuals, 
especially the elderly people had pre-existing humoral immunity to H1N1pdm09 
influenza virus before the pandemic (Ikonen et al., 2010). Since our study group 
was recruited between December 2009 and September 2010 when the pandemic 
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was ongoing, pre-existing immunity can indicate either a recent infection or cross-
reacting antibodies induced by previous influenza A virus infections. At four weeks 
after vaccination, our theoretical seroprotection rates (Table II, Publication III) 
increased and they ranged from 90 to 98% as determined by MAIA, EIA and the 
HI test. Six months after the vaccination, in 80% individuals (by HI test) and in 73-
83% (by EIA and MAIA) antibodies remained at theoretically seropotective level.  
We showed that the H1N1pdm09 vaccine induced very high seroprotection 
rates against the H1N1pdm09 virus in adults. As some previous studies show, 
seasonal influenza vaccines can induce little or no cross-reactive antibody response 
to new emerged influenza viruses (Hancock et al., 2009). When an antigenetically 
very different new influenza virus emerges (e.g. a pandemic of a novel seasonal 
influenza strain) it is important to estimate which fraction of the population has 
pre-existing immunity and evaluate the need and potential efficacy of seasonal 
vaccines. Since the immunoprotection against influenza virus is preferentially 
mediated by antibodies it is essential to follow-up influenza-specific antibody 
levels in the population. At present, the most common and widely used method for 
anti-influenza antibodies is the HI assay. The HI test is frequently used in 
diagnostic and research laboratories but it has certain limitations. HI assays are 
insensitive to agglutinate certain avian influenza A virus hemagglutinins and 
cannot detect human antibody responses to avian influenza viruses. Even high 
antibody titers after avian influenza infection or vaccination are failed to be 
detected by HI test (Rowe et al., 1999; Nicholson et al., 2001; Stephenson et al., 
2009). Beside this, inherently the reading of the HI test is subjective and the assay 
shows a large variation in HI endpoint titers between different laboratories 
(Hobson et al., 1972; Wood et al., 2012). In Study III we developed a multiplex 
immunoassay that has certain advantages compared to EIA and HI test in clinical 
vaccine trials and serosurveillance studies. The simultaneous detection of virus 
specific IgM and IgG in a single serum specimen tested at one dilution is a 
valuable tool in the diagnosis of virus infections and vaccine immune responses.  
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 Conclusions 
Serological studies are widely used to diagnose viral infections and to measure 
vaccine immune responses. Multiplexing technology is a globally emerging trend 
while enzyme immunoassay may stay as a conventional assay for certain more 
specific serodiagnostic applications. In the present study we developed a less time 
and labour consuming and cost effective multiplex immunoassay to carry out a 
large-scale serological follow-up of common respiratory infections in early 
childhood as well as simultaneous detection of anti-influenza IgG and IgM 
antibodies in an adult vaccination cohort. The study verifies the advantages and the 
potential of multiplex microarray immunoassay in large scale serosurveillance and 
vaccine immunity studies.  
 
The main conclusions are as follows: 
1. RSV accounts for a substantial proportion of respiratory infections in the 
child population. The burden of RSV infection is particularly great 
among young children aged <3 years. RSV reinfection rates are high and 
anti-RSV antibody levels decrease relatively rapidly. Young children 0-2 
years are an important target group for the development of RSV 
vaccines and antiviral drugs. 
2. The multiplex microarray immunoassay described in the present study is 
a specific, sensitive and rapid method for the simultaneous detection of 
multiple anti-viral antibodies in serum samples. We proved that the 
correlation of MAIA and EIA data is very high and therefore the MAIA 
is a promising alternative for the detection of antiviral antibodies in 
large-scale immunosurveillance studies.  
3. A great advantage of the MAIA is the possibility to determine antibodies 
to several virus antigens in a single microtiter plate well with small 
sample volumes and use very small amounts of antigens as compared to 
EIA. The performance of the MAIA was shown to be more cost-
effective than EIA.  
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4. We observed a high respiratory virus infection burden in very young 
children as evidenced by seropositivity in the MAIA assay. The rates of 
symptomatic infections, with the exception RSV, were relatively low 
based on virus-specific PCR assay. We can thus assume that a high 
proportion of infections are asymptomatic or relatively mild and the real 
rate of infection tends to be underestimated by PCR diagnostics. The 
lack of influenza A virus positive samples was partially explained by a 
high influenza vaccination coverage, which likely provided good 
protection against influenza A virus infection.  
5.   We developed an MAIA method for the simultaneous detection of IgM 
and IgG antibodies against several antigens in a single well. Our study 
demonstrated the ability of MAIA to effectively measure influenza A 
virus vaccine-induced IgM and IgG responses. MAIA data correlated 
very well with the ones of conventional EIA and HI assays and showed 
that MAIA is a good alternative to measure vaccine-induced immunity 
in large-scale vaccine studies.  
6. The MAIA method has the potential to be used in large scale 
epidemiological and seroprevalence studies to simultaneously detect 
immune response against multiple viral antigens and to differentiate 
acute infection with IgM positivity from past infection with only IgG 
positivity. In addition, the method can likely be used for detecting 
vaccine-induced immune responses basically to any vaccine antigen. 
MAIA is a new highly useful tool for diagnostics, seroepidemiological 
and vaccine immunogenicity studies that provides a lot of information 
on humoral immunity in a cost-effective manner.  
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